

# Best Practice Recommendations For Skin Health and Wound Management 2025

## CHAPTER 5



## Prevention and Management of Moisture-associated Skin Damage

---

**Louise Forest-Lalande** RN MEd NSWOC

**Laurie Parsons** MD FRCP(C)

**Sheri McPhee** RN BScN M.Ed NSWOC WOCC(C)

**Janet L. Kuhnke** RN BA BScN MS NSWOC DrPsychology

**Jasmine Hoover** BSc MLIS

**Tracy Lillington** RN BScN MN NSWOC Phd(c)

**Laura J. Dann** BPA-Human Services, Care Partner

Chapter 5  
Prevention and Management of Moisture-associated Skin Damage

**Authors:**

**Louise Forest-Lalande** RN MEd NSWOC

**Laurie Parsons** MD FRCP(C)

**Sheri McPhee** RN BScN M.Ed NSWOC WOCC(C)

**Janet L. Kuhnke** RN BA BScN MS NSWOC DrPsychology

**Jasmine Hoover** BSc MLIS

**Tracy Lillington** RN BScN MN NSWOC Phd(c)

**Laura J. Dann** BPA-Human Services, Care Partner

**How to cite**

Forest-Lalande L, Parsons L, McPhee S, Kuhnke JL, Hoover J, Lillington T, et al. Best practice recommendations for the prevention and management of moisture-associated skin damage. In: Kuhnke JL, Burrows CA, Evans RM, Orsted HL, Rosenthal S, editors. Best practice recommendations for skin health and wound management 2025. Toronto (ON): Wounds Canada; 2025. DOI: [10.56885/JWRY3671](https://doi.org/10.56885/JWRY3671)

© 2025 Wounds Canada. All rights reserved.

# INTRODUCTION

This best practice recommendation chapter is intended to aid teams in their ability to identify and differentiate the types of Moisture-associated skin damage (MASD), to identify those at risk for the various types of MASD and to become familiar with strategies to prevent and manage all forms of MASD. As well, it is intended to guide researchers to plan future projects.

Moisture-associated skin damage (MASD) occurs when the patient's skin is exposed to various sources of moisture.<sup>1</sup> MASD is an often overlooked and under-researched health concern.

MASD is often confused with pressure injury as a diagnosis. As well, the reporting of incontinence-associated dermatitis (IAD) is often inconsistent, as clinicians mistakenly document IAD as Stage 1 or 2 pressure injuries (PIs), this may account for variances in reported MASD prevalence.<sup>2</sup> As IAD often coexists with PIs and is suggested to increase the risk of damage associated with pressure, it is imperative that clinicians are able to differentiate between the two conditions. Friction, shear and pressure are contributing elements, often increasing the complexity of being able to accurately assess the etiology of the presenting MASD.<sup>3</sup>

MASD occurs when skin is exposed to moisture for prolonged periods of time, resulting in over-hydrated, inflamed skin (dermatitis) or eroded skin.<sup>4</sup> This leads to transepidermal water loss (TEWL) and an elevated skin pH that reduces the skin's ability to maintain its barrier function.<sup>5</sup> The result is separation of the skin layers, also known as maceration. Overhydration results in swelling to the stratum corneum, increasing the risk of irritants entering and further exacerbating inflammation.<sup>6</sup> The overhydrated stratum corneum is then at further risk of damage caused by friction or shear forces from objects such as bedsheets or incontinence pads.<sup>7,8</sup>

For more details on skin, please refer to [Chapter 3: Skin: Anatomy, Physiology and Wound Healing](#).<sup>48</sup>

Prolonged exposure to any type of moisture, such as water, perspiration, urine and/or feces (both), wound exudate, mucous, and saliva (i.e., irritant contact dermatitis due to saliva or irritant contact eczema due to saliva) may contribute to MASD.<sup>2,9-11</sup> The length of time moisture is in contact with the skin, combined with previous skin injury and mechanical and/or chemical factors such as friction, shear and composition of fluid, are key factors contributing to MASD development.<sup>2,12</sup> In addition, some patients with MASD may be suffering from underlying medical conditions (e.g., hypothalamus disorders, cancers, hypoalbuminemia, neurological disorders, edema/lymphedema, or hyperhidrosis [abnormally excessive sweating]) that affect the body's moisture production.<sup>13,14</sup>

Over-hydrated skin is more prone to mechanical damage caused by friction and shearing forces from skin rubbing against clothes, bedsheets or incontinence pads. The skin is more likely to break down and there is an increased risk of infection. Inflammation can also occur because normal skin flora is able to penetrate the skin barrier and activate the skin's immune defenses.<sup>12,15</sup>

In addition, known skin irritants are found in the various types of fluid, including inflammatory substances, digestive enzymes such as proteases and lipases, and micro-organisms. MASD is further linked with increased skin flora—such as coagulase-negative staphylococci and *Candida albicans*—that create an opportunistic environment for secondary infection.<sup>2</sup>

As the onset of MASD often goes undetected, it may first present as basic inflammation of the skin with or without skin breakdown.<sup>1,2</sup> It is often only when significant inflammation, maceration and/or skin breakdown emerge that clinicians take notice and intervene.<sup>2</sup>

Although the term *MASD* can be applied to any of the etiologies provided, five specific types of MASD are reported in the literature. Throughout this document MASD may refer to any one of the following:

- Incontinence-associated dermatitis (IAD)
- Intertriginous dermatitis (intertrigo or ITD)
- Periwound (e.g., peri-tube/drain and peri-fistula) MASD
- Peristomal MASD (e.g., colostomy, ileostomy/ ileal conduit, urostomy, suprapubic catheter, or tracheostomy, gastrostomy, nephrostomy)<sup>16</sup>
- Immersion foot, or trench foot (IF).

Moisture-associated skin damage can have a negative effect on patient wellbeing and quality of life.<sup>16</sup> Individuals with MASD experience persistent symptoms that affect quality of life, including pain, burning and pruritus.<sup>11,16,17</sup>

In the acute care setting, a recent prevalence study conducted in the United States found 34% of admitted patients had MASD incontinence-associated dermatitis {1.54%}, intertriginous dermatitis {2.66%}, peristomal MASD {0.14%}.<sup>18</sup> Another large-scale study addressing IAD, conducted in 448 nursing homes across 28 states in the United States, demonstrated an MASD incidence of 5.4%.<sup>2</sup> Of these individuals, 89% went on to develop IAD within 14 days of their first episode of onset of incontinence.<sup>19</sup> These studies highlight a need for further research of this issue.

**Note:** The reporting of skin that has been damaged by moisture is often inconsistent, as many clinicians mistakenly document it as Stage 1 or 2 pressure injuries (PIs).<sup>2</sup> This may account for variances in reported prevalence. As moisture damage often coexists with PIs and is suggested to increase the risk of damage associated with pressure, it is imperative that clinicians are able to differentiate between the two conditions. Friction, shear and pressure are contributing elements, often increasing the complexity of being able to accurately assess the etiology of the presenting MASD.<sup>3</sup>

Many risk and etiological factors for MASD overlap with those related to skin tears and pressure injuries. This best practice recommendation chapter does not address prevention and management strategies for skin tears or pressure injuries, but information can be found in [Chapter 6: Best Practice Recommendations for the Prevention and Management of Skin Tears](#) and [Chapter 4: Best Practice Recommendations for the Prevention and Management of Wounds: An Overview](#).<sup>49</sup>

It is assumed that the number of patients affected by MASD increases with age and comorbidities.<sup>20</sup> Yet, patient groups at high risk for MASD have complex health problems or multiple comorbid conditions, including older adults and those who are critically ill, with limited mobility, or receiving cancer treatment.<sup>21</sup>

## Types of MASD

**Incontinence-associated dermatitis (IAD):** Incontinence-associated dermatitis is a type of irritant contact dermatitis (inflammation of the skin) found in patients with urinary and /or fecal urinary incontinence.<sup>2</sup> The urea present in urine is transformed into ammonia by urease present on human skin. This reaction results in an elevation of pH that compromises the skin's protective acid mantle, thus reducing the chemical barrier effect of the skin.<sup>22</sup> Feces contain more water, proteolytic and lipolytic enzymes and is highly corrosive to the epidermis, with liquid feces having a higher concentration of water and these enzymes than formed feces.<sup>21</sup> These cofactors, in combination with excessive exposure to moisture, increase the risk of epidermal injury.<sup>23</sup> Literature supports a prevalence range of 5.6–50%, with the higher being related to fecal or dual incontinence (both fecal and urinary).<sup>24</sup> Despite high prevalence rates, incontinence and IAD rates are believed to be underreported due in part to lack of screening.<sup>25,26</sup> A key feature of IAD is erythema, the dilation of cutaneous blood vessels and pain, which is often described as burning, a common feature of ICD. Pain level increases with level of epidermal damage.<sup>27</sup>

**Intertriginous dermatitis (intertrigo or ITD):** Intertrigo is the result of friction in the presence of moisture. ITD can be very painful.<sup>28</sup> Areas of the body most susceptible are those where the skin is warm, trapped and where the skin is prone to friction.<sup>2</sup> Commonly areas affected include the axillary, inframammary, abdominal and inguinal folds.<sup>24,29</sup> The trapped moisture, normally caused by perspiration in the skin folds causes the skin surfaces to 'stick' together. This increases friction, leading to skin damage and inflammation, setting up a cycle that often becomes complicated by secondary infection.<sup>30</sup> Damage is typically mirrored on both sides of the fold.<sup>31,32</sup>

For patients with incontinence-related issues, the presence of lower body folds in the lower pelvic region may also contribute significantly to morbidity.<sup>24</sup> Obesity and diabetes are two conditions considered to be related to an increased risk for ITD as they are both prone to physiological skin changes, including higher rates of TEWL, increased sweat gland activity<sup>2</sup> and a higher surface pH in prone areas.<sup>24</sup> Although ITD has no race or gender predilection, it does tend to be more prevalent in geographic regions with hot and humid climates. ITD may be seen as a moisture-related issue independent of complicating factors; however, it is more commonly seen in combination with overgrowth of micro-organisms such as *Candida* species<sup>24</sup> or, less commonly, pathogenic bacteria.<sup>33</sup> In one acute care setting, ITD was prevalent in 2.66% of all reported cases of MASD.<sup>18</sup> The prevalence of ITD falls across a variety of sectors, with 20% of patients living in community dwellings, 17% in long-term care homes and only 6% in acute care settings.<sup>17</sup>

**Periwound MASD:** Periwound skin damage is multifactorial and often associated with irritant or allergenic contact dermatitis of the surrounding wound skin secondary to moisture. The presence of bacteria, specific proteins or proteolytic enzymes, as well as the volume of wound exudate greatly reduces the barrier function of the skin and can lead to maceration.<sup>15</sup> As well, the volume of wound exudate contributes to its presence.<sup>31</sup> Literature pertaining to the prevalence of periwound MASD is scarce, and the exact burden remains elusive. More research is needed.

Wound exudate is created during the natural process of the inflammatory phase of wound healing due to infection, inflammation or systemic edema.<sup>34</sup> When a wound is stalled, the concentration of metalloproteinases (a proteolytic enzyme) present in wound exudate increases, resulting in periwound skin damage and increasing the opportunity for maceration to occur.<sup>34</sup> When factors such as inadequate compression or inappropriate selection of wound dressings are present, wound exudate may not be well contained and can accumulate on the surface of the skin. When moisture becomes trapped under a dressing there are two factors to consider: the length of time between cleansing the periwound skin and applying the dressing may not be sufficient, or the dressing selected may not have adequate capacity to handle the amount of exudate present. Inadequate cover dressings may cause the wound exudate to seep back out of the dressing, especially as the level of compression over the dressing increases. The resultant dermatitis may exhibit mild damage in the form of erythema or may escalate to denudation of the epidermis with erosions, skin necrosis and blisters.<sup>3</sup>

**Peristomal MASD:** The major determinant of skin damage around a stoma is the enzymatic-containing effluent, although other contributory factors can also play a major role. These include mechanical trauma or medical-adhesive-related skin injury (MARS) from appliances, bacteria, underlying skin disorders, such as psoriasis or eczema, and the possibility of allergies to chemicals or fabrics.<sup>35</sup> A multifactorial etiology is common, with mechanical trauma, moisture and stoma effluent all working in tandem to break down the epidermal barrier.<sup>36</sup> This may occur post-operatively, and may reduce patients' ability to engage in self-management of the stoma. Alternatively, it may develop later if body shape changes because of weight loss or gain.<sup>31,32</sup>

Peristomal MASD affects approximately 50% of individuals with ostomies experiencing leakage.<sup>17</sup> A further study identified that approximately one-third of patients with a stoma who were followed up over a five-year study period had evidence of skin complications within 90 days of surgery.<sup>37</sup> Patients living with an ileostomy are more likely to experience peristomal MASD than were patients living with a colostomy.<sup>16,38</sup>

**Immersion Foot (IF):** Immersion foot, or trench foot as it is also known, is a syndrome secondary to prolonged foot exposure to moisture<sup>39</sup> and was first described in soldiers participating in trench warfare in the early part of the 20th century.<sup>40</sup> More recently, a rise in incidence has been noted among individuals who are experiencing homelessness and those living with untreated serious mental health issues.<sup>41,42</sup> Excessive sweating of the feet (hyperhidrosis), travelers, persons struggling to find a safe home, may also lead to IF.<sup>43,44</sup>

In IF, moisture damage to the stratum corneum, the outermost layer of skin, compromises barrier function. Prolonged exposure to wet conditions at temperatures above freezing results in peripheral neuropathy and microvascular damage.<sup>43,44</sup> IF may be further subdivided into that occurring only with prolonged exposure to water or in conjunction with severe cold injury. When occurring as a result of prolonged exposure to water alone, this pattern of damage is known as non-freezing cold injury (NFCI), as any prolonged exposure to water lower than normal body temperature can lead to localized hypothermia. Where temperatures are low enough to induce ice crystal formation in affected

tissues, the term freezing injury (FI) is used.<sup>45</sup> Frostbite is FI in the absence of prolonged exposure to water. Early symptoms of both types of IF are burning or stinging of the distal extremities. Progression to severe pain is most often associated with tissue ischemia. In more severe injury, cyanosis with significant swelling of the extremities has been well documented in published literature.<sup>46</sup>

Frostbite injury will not be discussed in this chapter (See [Chapter 8: Best Practice Recommendations for the Prevention and Management of Burns](#)).

This best practice recommendation is intended to aid interprofessional teams in their ability to identify and differentiate the types of MASD, to identify those at risk for the various types of MASD and to become familiar with strategies to prevent and manage all forms of MASD. As well, it is intended to guide researchers to plan future projects.

The recommendations that are included in this chapter are based on the best available evidence and are intended to support the clinician and integrated team in planning and developing best practices in the prevention and management of MASD. For more information see [Chapter 4: Best Practice Recommendations for the Prevention and Management of Wounds: An Overview](#).<sup>49</sup>

This chapter is written with the intent to encompass the quintuple aim for health care improvement. This is to enhance the patient experience, reduce costs, improve population health, improve the clinician experience and enhance equity (see [Table 1](#)). This equity component is particularly important for patients living at risk for, or with, skin issues, wounds and specifically MASD. Ensuring all patients receive care, supplies and ongoing preventative strategies needs to be recognized and communicated to policy makers.<sup>47</sup>


**Table 1:** Quintuple Aim and Management of Moisture-Associated Skin Damage

5 components	Applied to Moisture-Associated Skin Damage
Improving population health	Through prevention, education and self-management strategies
Reducing costs	Application of best practice to ensure most effective treatment Appropriate use of resources-examples products, dressings, devices
Advancing health equity	Application of principles to all those at risk or affected by moisture-associated skin damage
Care team well-being	Providing clinically usable information for front line clinicians
Enhancing the patient experience	Providing a supportive process of care for all those with moisture-associated skin issues

## THE WOUND PREVENTION AND MANAGEMENT CYCLE

This chapter offers a practical, easy-to-follow guide that incorporates the best available evidence. It outlines a process, or series of consecutive steps, that supports patient-centred care using a process called the Wound Prevention and Management Cycle (See [Figure 1](#)), which guides the clinician through a logical and systematic method for developing a customized plan for the prevention and management of wounds, from the initial assessment to a sustainable plan targeting self-management for the patient.<sup>48</sup>

**Figure 1:** The Wound Prevention and Management Cycle



The recommendations in this chapter are based on the best available evidence and are intended to support the clinician, the patient, care partners, their family, and the health-care team in planning and delivering the best clinical practice.

Two foundational chapters supplement this chapter with additional evidence-informed information and recommendations that are general to all wound types. These are: Chapter 3: Skin: Anatomy, Physiology and Wound Healing<sup>48</sup> and Chapter 4: Best Practice Recommendations for the Prevention and Management of Wounds: An Overview.<sup>49</sup>

Three guiding principles, within the best practice recommendation papers, support effective prevention and management strategies for skin breakdown:

1. Utilization of the Wound Prevention and Management Cycle regardless of the specifics to prevent and manage skin breakdown,
2. Consistent, accurate and multidirectional flow of pertinent information within the health-care team and across settings, and
3. Ensuring the patient remains the core of all decision making.

## Step 1: Assess and/or Reassess

The following section provides information for each of the five types of MASD: IAD, ITD, peristomal MASD, periwound MASD and immersion foot (IF). Each type of MASD will be treated separately according to the best available evidence for each type.

### Recommendations

#### 1.1 Select and use validated patient assessment tools

Keeping a patient's skin intact is a priority in delivery of care.<sup>50</sup> This occurs through regular skin assessments and assessment of *direct risk factors* (body fluids, skin cleansing procedures and products) and mechanical factors, and *indirect risk factors* such as age, dependency, mobility, nutritional status, body mass index, medical conditions, pain, sensory changes and immunosuppression.<sup>20</sup> Skin assessments are completed by conducting routine head-to-toe skin checks (documenting skin tone) and assessing pain, risk of infection at regular intervals.

The literature has identified validated assessment tools pertaining to MASD. Pain, nutrition and quality of life (QoL) assessments should be performed with each type of MASD.<sup>49</sup> See Chapter 4: Best Practice Recommendations for the Prevention and Management of Wounds: An Overview.<sup>49</sup> Researchers suggest pain is present in 25% of those with periwound MASD, likely as a direct result of periwound skin damage and consequent local inflammatory reactions.<sup>17</sup> Increased pain can drastically reduce QoL and overall patient and clinician experience, negatively impacting participation in the plan of care.<sup>51</sup> Given the strong link between malnutrition and delayed wound healing, and the fact that MASD is a form of altered skin integrity, clinicians should assess the nutritional status of individuals with MASD<sup>52</sup> especially older adults.<sup>53</sup>

See Appendix: Nutrition for Skin Health, Wound Prevention and Wound Healing in Chapter 4: Best Practice Recommendations for the Prevention and Management of Wounds: An Overview.<sup>49</sup>

Staging and categorization tools are as important as validated assessment tools, as each stage or categorization works to standardize the language used when documenting, defines the state of a wound and may help to guide interventions. Where available, both staging or categorization and assessment tools should be used. Table 2 provides a list of evidence-based validated tools.

**Table 2:** Categorization and Assessment Tools for the Different Types of MASD

	Categorization Tool	Assessment Tool	Tool validation
<b>Incontinence Associated Dermatitis (IAD)</b>	Ghent Global IAD Monitoring Tool	Ghent Global IAD Monitoring Tool	Yes
	Perineal Assessment Tool (PAT)		Yes (valid, reliable)
<b>Intertriginous dermatitis (ITD)</b>	None available	None available	
<b>Periwound Moisture-Associated Dermatitis (MASD)</b>	None available	None available	
<b>Peristomal MASD</b>	The SACS™ Instrument	The SACS™ Instrument	Yes
	DET Score	DET Score	Yes
	AIM (Ostomy Skin Tool)	AIM (Ostomy Skin Tool)	Yes
<b>Immersion Foot (IF)</b>	None available	None available	



**Incontinence-associated dermatitis (IAD):** A variety of tools are available to aid the clinician in identifying IAD or risk factors for the prevention of IAD. Implementing a validated assessment tool into practice may prevent unnecessary delays in identifying the risk or correct etiology of existing damaged skin. This is important, as IAD is often misdiagnosed as a PI and/or skin tear.<sup>54</sup>

The Perineal Assessment Tool (PAT) was developed to assess the risk of IAD using four main criteria: 1) type and severity of irritant, 2) length of exposure, 3) existing condition of the skin and 4) other factors such as the use of antibiotics, presence of *Clostridium difficile* diarrhea, low serum albumin and tube feeding.<sup>2,54</sup> The PAT demonstrated content validity and adequate interrater reliability; however, opinions differed on the frequency of use, and information was not reported to support the tool's predictive validity.<sup>56,57</sup>

The Perineal Dermatitis Grading Scale is a descriptive tool used to evaluate four parameters of IAD: erythema, skin integrity, measurement (cm) of the affected area(s) and symptoms experienced by the patient.<sup>11</sup> Another description tool reported in the literature is the IAD Skin Condition Assessment Tool.<sup>11</sup> Designed to measure the severity of IAD, this tool includes three of the four parameters included in the Perineal Dermatitis Grading Scale: erythema, affected area(s) and presence of skin damage. There do not appear to be validation studies for either of these tools.<sup>11</sup>

The validated Ghent Global IAD Categorisation Tool (GLOBIAD), currently available in 19 languages, suggests any patient with any form of incontinence and intact skin should be considered Category 0, placing them automatically at risk of IAD.<sup>22</sup> Category 1 and 2 are based on the duration of erythema and damaged skin, respectively, with both categories further subdivided based on the presence of clinical signs of infection. Using this tool to differentiate between categories demonstrated a sensitivity and specificity of 90% and 84%, respectively.<sup>58</sup> Overall, interrater reliability was 0.41, intrarater reliability 0.61 and agreement was 0.86 for the tool.<sup>58</sup>

The Skin Integrity Research Group (SKINT) based out of Ghent University took the GLOBIAD, combined it with a core outcome set, and developed the GLOBIAD-M, an outcome assessment tool to measure change,<sup>59</sup> providing clinicians with a standardized way to monitor their interventions when treating IAD. The GLOBIAD-M demonstrated good interrater agreement and reliability when photographs were assessed by experts<sup>59</sup> providing an innovative assessment tool that can be used virtually in regions without immediate access to expert clinicians.

The Incontinence Associated Dermatitis and its Severity tool is used to generate a score between 0 and 52 using 13 locations on the body and assessing for redness, skin loss and presence of rash.<sup>17</sup> Face validity and content validity were determined.<sup>60</sup> Inter-rater reliability was also tested; however, the method used for statistical analysis was not provided. Criterion validity was determined using four case scenarios; agreement was 0.98.<sup>60</sup>

**Intertriginous Dermatitis (ITD):** To date, there are no validated risk assessment tools for ITD, but common risk factors include hyperhidrosis, large skin folds, obesity, diabetes mellitus, poor hygiene and malnutrition. Hot, humid environments also increase the chances of developing ITD and increase the risk for those with the above-mentioned conditions.<sup>61</sup>

**Periwound MASD:** There are various valid and reliable wound documentation tools that include parameters such as the periwound skin, wound edges and exudate characteristics. Tools such as the revised Photographic Wound Assessment Tool (PWAT),<sup>62</sup> Bates-Jensen Wound Assessment Tool (BWAT),<sup>63</sup> and the Pressure Ulcer Scale for Healing (PUSH)<sup>64</sup> are available. However, none of these have been validated for outcome measures for MASD.

**Peristomal MASD:** The DET Score Tool<sup>65</sup> measures: 1) a discolouration, erosion and tissue overgrowth (DET). The DET Score is intended to measure the extent and severity of peristomal skin damage as a real-time assessment and was developed by an international group of 12 stoma care specialty nurses.<sup>66</sup> Martins et al. recently reported new statistical analysis of the OST version 2.0.<sup>67</sup>

The Peristomal Skin Assessment Guide (PSAG) for clinicians is available on the WOCN website <https://psag.wocn.org/index.html#home>. This guide has been developed to help standardize assessment, identify probable reasons for the complications and provide simple management options. Another validated classification system is the studio

alterazioni, cutanee, peristomali (SACS) study on peristomal skin lesions.<sup>68</sup> Criterion validity was determined, and its ability to accurately categorize was measured and evaluated to be very good.<sup>69</sup> This tool enables clinicians to assess and classify peristomal skin lesions from urine or fecal sources.

To date, there are no validated assessment or categorization tools available for gastrostomies, tracheostomies, drains, tubes or fistulas.

**Immersion foot (IF):** Currently there are no risk assessment tools for immersion foot. Certain populations are known to be at higher risk, such as persons experiencing homelessness (living unsheltered, emergency shelters, provisionally accommodated, or being at risk of homelessness), and those with poorly managed mental illness such as schizophrenia, depression, and complicated by substance use.<sup>42</sup> For frostbite injuries, a classification system is available to identify grades of injury.

## **1.2 Assess skin health and identify risk and causative factors that may impact skin integrity and wound healing**

Obtaining a detailed history in all areas of the biopsychosocial spectrum, in combination with a comprehensive physical examination, is essential in discovering all intrinsic and extrinsic causative factors. Only when these underlying factors are identified can a plan of care geared toward evidence-based prevention and treatment be developed for risk and causative factors associated with the healing process.

### **1.2.1. Patient: Physical, emotional and lifestyle**

#### **Physical Assessment**

Begin by assessing skin health status by conducting a head-to-toe assessment. Discuss skin issues with the patient, care partner and family. This includes a focused patient history including cognition, medications, continence status to identify any risk factors for MASD.<sup>50</sup> A physical assessment should include a skin assessment that takes into consideration the level of hydration (e.g., dryness, flaking, maceration), baseline skin tone, redness, areas of denudement, number of lesions, symmetry, location of changes, odour, periwound skin and skin colour changes, and the patient's ability to perform head-to-toe skin care.<sup>48</sup> Assess and identify the source or potential source of moisture to determine the level of risk for any type of MASD, as a plan of care to treat and prevent MASD depends on the moisture's origin. For those experiencing peristomal or periwound MASD, removal of any dressings or appliance and thorough cleansing of the area is required before inspecting the skin. Once the origin has been identified, implement steps to reduce the presence of moisture to protect skin integrity and support the wound healing process.<sup>70</sup>

A comprehensive assessment must differentiate MASD from other underlying etiologies, such as PIs. MASD is a major contributing factor known to increase the effects of pressure, and many expert clinicians report the average bedside clinician is not able to differentiate between the two.<sup>71,72</sup>

#### **Incontinence-associated dermatitis (IAD)**

According to Beeckman et al., any individual with urinary and or fecal incontinence is considered Category 0 (at risk for IAD)<sup>70</sup> therefore, performing a regular, focused genitourinary assessment may be warranted to identify any variation in skin condition and avoid ensuing skin damage. Common locations for skin damage secondary to IAD are the sacrum, perineum, thighs and buttocks. Broken skin is at higher risk for secondary bacterial infection.<sup>2</sup> During the physical assessment, the category of breakdown should be documented according to the GLOBIAD Categorization Tool.

Physical assessment should also include mobility and range of motion to determine the level of functional incontinence.<sup>2,70</sup> Obtain any previous urodynamic testing and imaging, and conduct a pelvic floor assessment to determine any factors contributing to incontinence.<sup>72</sup> Refer the patient to a nurse continence advisor.

## Intertriginous Dermatitis (ITD)

The assessment of risk and/or diagnosis of ITD begins with a review of the patient's medical history and a thorough physical examination with a focused skin assessment. During the skin assessment it is essential to include careful visual examination of axillae, groin, gluteal cleft, inframammary and abdominal folds, as well as labiocrural folds (where the labia majora and the inner thighs meet).<sup>71</sup> Ruling out other various skin disorders is important, as many mimic the appearance of intertrigo but may require urgent intervention. Misdiagnosis can result in a significant adverse event.

A comprehensive skin assessment and the ability to differentiate between IAD and ITD is imperative, especially as these conditions may overlap. Friction, the force of two surfaces moving across one another (such as the mechanical force exerted when the body is dragged across another surface), can place a patient at increased risk of MASD secondary to ITD.<sup>72</sup> Friction in the presence of moisture creates an optimal environment for *Candida albicans* to grow (See Table 2: Categorization and Assessment Tools for the Different Types of MASD).

Clinically, a cutaneous superficial *Candida* infection would appear as an erythematous patch, often shiny, with satellite vesicopustules prone to easy rupture.<sup>33</sup> In contrast, IAD spares creases and folds, except when superimposed with a *Candida* infection. Although clinical assessment is typically sufficient to provide a diagnosis, a scraping for microscopic examination may be required to confirm the organism as *Candida albicans*.<sup>33</sup> During assessment for ITD the patient should lie in supine position to allow for all skin folds to be visualized.<sup>2</sup> For patients with a larger body size inspect the skin folds (e.g., neck, arms, abdomen, groin, legs, toes). It is always safer to enlist the help of another clinician, where feasible, to help lift any folds and avoid further friction-related trauma.<sup>2</sup>

## Periwound MASD

A comprehensive skin assessment should include inspection and documentation of the periwound skin and wound edges. Skin breakdown and excess moisture can lead to periwound inflammation and erythema, as wound exudate contains proteolytic enzymes that can break down intact skin.<sup>34</sup> Include in the focused wound assessment the amount and type of drainage and attempt to identify the causative factor(s) so you can create a plan to reduce them.

Periwound skin changes may also occur from using dressings that do not support the level of drainage or when clinicians do not allow the skin adequate drying time prior to the application of an adhesive or silicone-bordered dressing.

Macerated skin is more permeable to micro-organisms and prone to damage from friction and irritants than intact skin.<sup>34</sup>

Periwound skin damage from moisture leads to inflammation and denudation of the skin adjacent to the wound edge (within 10 cm of the wound edge) and secondary to exposure of wound exudate. Periwound skin damage is evident from the varying degree of skin maceration, erythema, edema, inflammation, denudation and destruction.<sup>73</sup> Currently there is no standardized tool to measure or assess periwound skin damage; however, such an assessment is similar to a wound assessment.

For instance, non-advancing wound edges are a common sign indicating excessive moisture. Erythema will present differently in those with darker skin pigmentation, so it may be more useful to consider hyper- or hypo-pigmentation when performing a periwound skin assessment.<sup>34</sup> Assessment characteristics in the PWAT and BWAT both include those directly related to edge effect and appearance.<sup>62,63</sup> The BWAT also includes assessment of wound exudate including exudate type and amount.<sup>63</sup> Although the BWAT is a great descriptive tool, the PWAT score provides the clinician with an objective score indicating whether the wound is improving or deteriorating.

## Peristomal MASD

Peristomal skin must be regularly assessed (either by the patient during self management, care partner or clinician) by performing a physical assessment. Peristomal skin damage is routinely assessed as part of ostomy (colostomy,

ileostomy, urostomy, gastrostomy or tracheostomy), tube, drain and fistula care. MASD in a peristomal location incorporates the skin surface area that may extend out from the base of the stoma, in a circumferential manner.<sup>65</sup> Assessment of the peristomal skin includes inspection and palpation. Complications can be related to several etiological factors. Maceration is secondary to prolonged exposure to moisture, which is secondary to effluent from the stoma.<sup>74</sup> This can be related to inadequate application of the containment product or medical device. Caustic changes can occur to the peristomal skin when in contact with urine or feces, since the effluent contains chemicals and a high volume of enzymes and bacteria.<sup>74</sup>

In addition to stomal effluent, perspiration is a source of moisture contributing to peristomal MASD. Begin the assessment with visual inspection of the skin and stoma, including skin colour and integrity and stoma location, size, protrusion and shape.<sup>34</sup> A primary factor to assess is the ability of the chosen appliance to contain the effluent and ensure the peristomal skin remains dry and intact.<sup>75</sup>

Note also if there is evidence of a fungal infection. Table 3 presents examples of peristomal fungal infections.

**Table 3:** Examples of Peristomal Fungal Infections (Used with permission from Louise Forest-Lalande.)

Fungal infection	Peristomal skin erosion and fungal infection occurring under the skin barrier
	
Fungal infection around a tracheostomy	Peristomal skin erosion/inflammation and extended skin fungal infection under the skin barrier
	

Used with permission from Louise Forest-Lalande.

### Immersion Foot (IF)

An important part of the overall assessment of patients with this type of complication is to identify additional potential life-threatening injury prior to focusing on the extremities.<sup>39</sup> Begin with a comprehensive physical, mental status and social assessment. Signs of neglect such as poor hygiene, broken nails and poor skin quality should trigger an assessment for malnutrition and other risk factors for IF.<sup>76</sup> Other identified factors for IF are tight and poor-quality

clothing and wearing footwear (boots, shoes, sandals, wet socks) inappropriate for ambient weather conditions, obesity, urine and/or feces accumulating in footwear, inability to provide good foot inspection and hygiene, excessive foot sweating (extrinsic and intrinsic), living alone, poor mental health status and low socioeconomic status.<sup>39,40-42</sup>

Clinicians should follow this with assessment for skin quality, pain and vascular status of the affected limb.<sup>77</sup> Reduced pulse quality or capillary refill should prompt referrals for vascular assessment. Evaluate severe injury with angiography, ultrasound and bone scan.<sup>77</sup>

### Emotional and Lifestyle Assessment

All forms of MASD are linked to diminished quality of life, so clinicians should assess for this as well: IAD can result in significant discomfort or pain, increasing the reliance on health-care providers and facilities.<sup>78</sup> ITD, with its associated itching, can lead to high rates of secondary fungal infections.<sup>79</sup>

The psychosocial effects on an individual with MASD, regardless of type or etiology, need to be sensitively explored as early as possible.<sup>80</sup> Perform a psychological assessment to assess the level of impact of MASD on QoL of the patient, the family and the care partners.<sup>80,81</sup> MASD can result in severe limitations on the activities of daily living as well as various other social activities, such as dining out, traveling or engaging in intimate and/or sexual activity.<sup>81</sup> Barrow points out that detrimental psychological effects are far less common in people who feel like they have an influence on their situation and can participate in planning the next steps.<sup>82</sup> Modifiable risk factors can be defined as those within an individual's ability to change by making lifestyle adjustments. These may include weight, activities deemed harmful, such as smoking, and diet. Non-modifiable risk factors would include those that cannot be controlled through lifestyle changes such as congenital conditions and non-reversible physiological impairments. See Table 4 for a summary of risk and causative factors for MASD.

#### 1.2.2. Environmental: Socio-economic, care setting, potential for self-management

Patients with predisposing dermatological issues, previous pressure injuries, dermatitis (contact with urine and/or feces), cutaneous fungal and/or bacterial infections may be more prone to developing some forms of MASD.<sup>20</sup> Populations at higher risk are those who have limited access to the health-care system (e.g., accessing home care in remote and rural regions, those experiencing homelessness). Fortunately, there is an increasing recognition related to diversity in health care and culturally sensitive care has become the standard in many regions and health-care facilities throughout the world.<sup>83</sup> Those new to Canada, undocumented immigrants, individuals with low income, those who are uninsured or underinsured and those with low literacy are associated with poor health outcomes and the ability to provide self-managed care.<sup>84</sup> These factors compound for those considered to be of low socioeconomic status and directly impact the ability to fund the required items to aid in preventing MASD. See Table 4 for modifiable, non-modifiable and causative factors for MASD.

**Table 4:** Modifiable, Non-modifiable and Causative Factors for MASD

Type of Moisture-Associated Dermatitis (MASD)	Modifiable Risk/ Causative Factors
<b>IAD</b>	<ul style="list-style-type: none"> <li>• Urine and or feces are the two primary sources of moisture</li> <li>• Urinary and/or fecal incontinence combined with friction between the skin and an absorbent product</li> <li>• Urinary incontinence</li> <li>• Fecal incontinence provides greater risk of exposure to digestive enzymes present in feces that accelerates skin breakdown</li> <li>• Aged skin, altered skin oxygenation, fever, air flow restriction, decreased mobility</li> <li>• Prolonged use of steroids, antibiotics or promotility agents</li> <li>• Impaired functional, emotional or cognitive status and/or mobility<sup>19</sup></li> </ul>

<b>ITD</b>	<ul style="list-style-type: none"> <li>• Perspiration is the most associated source of moisture<sup>11</sup></li> <li>• Often the result of moisture combined with areas of high friction</li> <li>• Risk factors include high body mass index, lymphedema, multiple skin folds, pendulous breasts</li> <li>• Those who are malnourished, immobile, have poor hygiene or diabetes mellitus<sup>61,85</sup></li> <li>• Hyperhidrosis, or profuse perspiration<sup>85</sup></li> <li>• Hot and humid climates<sup>85</sup></li> </ul>
<b>Periwound MASD</b>	<ul style="list-style-type: none"> <li>• Wound exudate is the most common source<sup>11</sup></li> <li>• Chronic wounds contain higher amounts of proteolytic enzymes<sup>3</sup></li> <li>• Occlusive wound care dressings or products that increase the level of moisture to an excessive amount</li> <li>• Individuals at higher risk include the elderly, the immunocompromised, or those with previous environmental skin damage (radiation, sun exposure), skin disorders (eczema, psoriasis), underlying pathology and congenital disorders (epidermolysis bullosa)<sup>34</sup></li> </ul>
<b>Peristomal MASD</b>	<ul style="list-style-type: none"> <li>• Primary source of moisture is stoma effluent: urine, feces or mucus<sup>6</sup></li> <li>• Saliva and respiratory secretions in those with tracheostomies<sup>24</sup></li> <li>• Ill-fitting or leaking appliance</li> <li>• Stoma placement embedded within skin folds, flat or retracted stomas<sup>6</sup></li> <li>• Fluctuation in weight, change in abdominal circumference<sup>6</sup></li> <li>• Untrained clinicians and new ostomates applying appliances<sup>11</sup></li> <li>• Gastric leakage from gastrostomies<sup>35</sup></li> <li>• Peri-drain/tube drainage<sup>11</sup></li> </ul>
<b>Immersion Foot (IF)<sup>86</sup></b>	<ul style="list-style-type: none"> <li>• Wearing wet footwear and or socks for prolonged periods of time</li> <li>• Leg edema, skin folds, higher body mass index (obesity)</li> <li>• Urine and/or feces (both) accumulating on legs and in footwear</li> <li>• Reduced mobility</li> <li>• Lack of support to perform foot hygiene</li> <li>• Excessive foot perspiration</li> <li>• Insecure housing and experiencing homelessness</li> <li>• Plaster casts</li> <li>• Long wear time of combat, construction, fishing, or rubber boots<sup>41</sup></li> </ul>

With health care shifting into the community sector, an aging population and a consistent lack of qualified clinicians in the community sector, it is increasingly necessary for patients to participate in self-managed care.<sup>87</sup> For those with MASD, a precipitating factor is the ability to perform self-managed personal hygiene and bowel and bladder routines.<sup>50</sup>

### 1.2.3. Systems: Health-care support and communication




Support from all levels of a health-care system is imperative for effective prevention and management strategies related to all forms of MASD. Currently provincial/territorial legislation mandates that organizations report on the incidence and prevalence of PIs but not for other nosocomial injuries such as skin tears or MASD. Although guidelines exist in some provinces/territories, it is not mandated that organizations report metrics. Standardized language is a critical component of effective communication between clinicians and organizational leaders.<sup>88</sup>



Clinicians require education and tools to be able to differentiate not only among PIs, skin tears and MASD, but also among the types of MASD. Standardized language and descriptions result in more accurate and consistent documentation, increasing the opportunity to perform more accurate data collection and, where a clear description of a problem is reported, for a clinician to provide evidence-based interventions.<sup>89</sup> Tay and colleagues reported the Knowledge, Attitudes, and Practices of IAD Questionnaire (KAP-IAD-Q) to have good psychometric properties when measuring nurse knowledge, attitudes and practice.<sup>90</sup> Such tools support teams to measure KAP among nurses working with patients at risk of developing IAD; more research is needed utilizing this tool.

### 1.3 Complete a skin/wound assessment, if applicable

Complete a comprehensive and focused skin assessment to determine the specific subtype of MASD and etiology (See Table 5). This should include, but may not be limited to, maceration, pain, erythema and level of erosion including dermatitis.<sup>91</sup> Where validated staging or categorization tools exist (GLOBIAD for IAD, or OST (2.0), or SACS for ostomies), documenting the stage or category is essential to accurately collect data and to enhance communication through standardized language. Thorough cleansing of the area prior to a focused wound assessment will improve accuracy in identifying the level of tissue involvement and drainage type. Note the wound edges and appearance or breakdown of surrounding skin. These areas of breakdown are difficult to measure, as they often have no depth and are quite large and irregular in shape, spanning both sides of an area. Location of the affected area(s) will enable identification of the type of MASD present. A skin biopsy can be an important diagnostic tool in the diagnosis of a wide array of inflammatory skin conditions and irritant dermatitis such as IAD and ITD; however, it cannot reliably discriminate between the two. Diagnosis should be based on clinical features with judicious use of percutaneous skin testing for contact dermatitis related to irritants and allergies.<sup>92</sup>

**Table 5:** Comparison of MASD Clinical Subtypes (Used with permission from Kimberly LeBlanc and Laurie Parsons.)

MASD Type	Appearance	Clinical Features
<b>IAD</b> <sup>70 *</sup>		<ul style="list-style-type: none"> <li>• Location: perineum, labial folds in women, scrotum in men, buttocks, gluteal fold, medial and posterior aspects of upper thigh, lower back<sup>1,2,50</sup></li> <li>• Erythema and inflammation of the affected area(s) with or without skin breakdown<sup>1</sup></li> <li>• Discomfort, pain, itching, burning.<sup>19</sup> Prone to secondary infections<sup>19</sup></li> <li>• Extreme cases: swelling and blister formation may occur<sup>3</sup></li> </ul>
<b>ITD</b> <sup>61 *</sup>		<ul style="list-style-type: none"> <li>• Location: axilla, inframammary, abdominal and inguinal folds, pubic panniculus, gluteal cleft and areas prone to harbour moisture</li> <li>• Less common locations include interdigital, eyelids, antecubital, retro auricular<sup>33</sup></li> <li>• Starts as mild erythema and can progress to severe swelling with maceration, denudation, weeping and crusting with potential secondary infection<sup>3</sup></li> <li>• Centralized erythema with satellite lesions often associated with candida albicans</li> <li>• Itching, burning, pain and odour</li> <li>• Chronic subtle onset of pruritus, burning, tingling and pain in the skin folds<sup>93</sup></li> </ul>
<b>Periwound MASD</b> <sup>94 **</sup>		<ul style="list-style-type: none"> <li>• Erythema and inflammation of the skin surrounding the wound up to 4 cm from the wound edge<sup>95</sup></li> <li>• Maceration appears as reversible pallor secondary to excessive moisture and wrinkled skin<sup>1</sup></li> <li>• Edge migration may be diminished</li> <li>• Hypergranulation tissue may be present within the wound edges</li> <li>• Hyper- or hypo-pigmentation of the surrounding intact skin<sup>34</sup></li> </ul>

<b>Peristomal MASD<sup>34</sup> **</b>		<ul style="list-style-type: none"> <li>• Location begins at the stoma-skin junction and may extend outward by up to 10 cm around the stoma<sup>34</sup></li> <li>• Includes urinary and fecal diversions, tracheostomies and other stomas</li> <li>• Erythema and inflammation of the peristomal skin with or without skin breakdown<sup>11,21</sup></li> </ul>
<b>Immersion Foot (IF)<sup>96</sup> **</b>		<ul style="list-style-type: none"> <li>• Begins as tingling, itching and/or numbing feeling<sup>40</sup></li> <li>• Erythema or cyanosis with appearance<sup>40</sup></li> <li>• Feet may appear doubled in size as a result of edema</li> <li>• Burning, pain</li> <li>• Mild to moderate to severe blistering</li> <li>• Petechiae</li> <li>• Numbness<sup>42</sup></li> </ul>

\*Used with permission from Kimberly LeBlanc.

\*\*Used with permission from Laurie Parsons.

### Severity of MASD

MASD may be categorized as mild, moderate or severe and can occur across the lifespan, though it is more common in the extremes of age.<sup>97</sup> Mild MASD presents with red, irritated and inflamed intact skin. Moderate and severe MASD are more complex and present with blistering and erosion and/or denudation of the epidermal to dermal layers of skin.<sup>55</sup> Once the damage has compromised the protective barrier function of the skin, secondary fungal or bacterial infection can occur. The challenge with classifying MASD as mild, moderate or severe is that this is based on a subjective assessment by the clinician; one clinician may interpret the signs as mild while another may interpret them as moderate. The negative impact MASD has on human life includes mild pain to severe discomfort, loss of dignity and reduced quality of life. The economic burden associated with the care and management of MASD is considered by many to be high; yet, to date, the full complexity and scope of this problem is not fully understood.<sup>16</sup>

## Step 2: Set Goals

### 2.1 Set goals to maintain skin health and for prevention and healing, non-healing and non-healable wounds

Please see Chapter 4: Best Practice Recommendations for the Prevention and Management of Wounds: An Overview<sup>49</sup> for the definition of healable, non-healing and non-healable wounds.

Primary goals should focus on prevention and include a distinct skin care routine and nutrition (food/fluid) strategy in conjunction with methods of reducing friction and moisture within the affected areas.<sup>2,72</sup> Bliss and colleagues were able to demonstrate this for IAD in a nursing home population, where results showed that participants following regular skin care regimens as a method of prevention were 46% less likely to develop IAD.<sup>19</sup> In cases complicated by opposing skin surfaces and increased friction, such as ITD, donning products designed to reduce friction and wick away moisture may reduce the risk of developing complications.<sup>3</sup> Outcomes on the use of moisture-wicking fabrics, however, have not been reported in the literature.<sup>17</sup> Voegeli also supports the adoption of a regular skin care protocol, controlling the cause of moisture and treating and preventing any secondary infection.<sup>3</sup> For IAD, continence control is the key to successful management and prevention. Referral to a pelvic floor physiotherapist may allow for strengthening of the pelvic floor muscles. In some instances, a urinary or fecal diversion may be necessary.<sup>72</sup>

See Table 6 for a breakdown of examples of goals to be considered for each type of MASD.



**Table 6: SMART\* Goals for MASD**

Type of MASD	Goals
<b>IAD</b>	<ul style="list-style-type: none"> <li>Prevent skin breakdown related to IAD</li> <li>Manage incontinence within 1 week</li> <li>Restore skin integrity within 2 weeks</li> </ul>
<b>ITD</b>	<ul style="list-style-type: none"> <li>Prevent skin breakdown related to ITD</li> <li>Keep skin folds dry within 1 day</li> <li>Reduce the amount of friction in intertriginous areas within 1 day</li> <li>Resolve secondary infection if appropriate within 5 days</li> </ul>
<b>Periwound</b>	<ul style="list-style-type: none"> <li>Prevent periwound skin maceration</li> <li>Manage periwound skin maceration</li> <li>Resolve secondary infection if appropriate within 5 days</li> </ul>
<b>Peristomal</b>	<ul style="list-style-type: none"> <li>Prevent peristomal skin maceration</li> <li>Restore healthy peristomal skin</li> <li>Resolve secondary infection if appropriate within 5 days</li> </ul>
<b>Immersion Foot (IF)</b>	<ul style="list-style-type: none"> <li>Prevent further damage related to IF</li> <li>Restore skin barrier function</li> <li>Ensure wearing of appropriate footwear and socks within 2 days</li> </ul>

\***SMART** stands for Specific, Measurable, Achievable, Realistic and Timely

### 2.1.1 Identify goals based on prevention or healability of wounds

All MASD types should be considered healable, as the underlying factor is moisture secondary to a variety of mainly controllable factors, and the primary goal should be the prevention of future episodes of skin breakdown through methods of moisture control. When determining healability and establishing goals it is important to determine if patients and caregivers will be able to manage moisture on their own if they are provided relevant education and resources<sup>61,98</sup> as this will directly impact the goal setting activity and expected outcomes.<sup>50</sup>

In settings where licensed health-care professionals are present, all new cases of MASD should be given independent consideration and be considered a nosocomial injury to the patient. Most institutions are mandated to audit for PIs on an annual basis; however, clinicians generally do not use this opportunity to document other prevalent skin injuries such as MASD or skin tears. Prevention of all categories of incontinence-associated dermatitis begins with a continence assessment including a functional assessment of the patients' ability to toilet and to regain or maintain their ability to toilet.<sup>73,99</sup>

### 2.1.2 Identify quality-of-life and symptom-control goals

Clinicians must work with the patient and develop an individualized plan of care, always considering the patient's quality of life, values and wishes for treatment. Organizations investing in evidence-based skin care protocols are more likely to improve patient experience, increase the number of positive clinical outcomes and drastically increase the quality of life for those living with MASD.<sup>27,100</sup>

## Step 3: Assemble the Team

### 3.1 Identify appropriate health-care professionals and service providers

In constructing a team, clinicians need to consider all available team members when developing an individualized plan of care. Table 7 summarizes the role of each team member as it pertains specifically to MASD. Respectful and trusting partnerships among patients and health-care professionals is crucial in obtaining patient buy-in and agreement to engage in self-care strategies.<sup>101</sup> All team members including the patient and care partners should be provided with

education and support to ensure their knowledge and understanding of MASD is current and in alignment with best practice.<sup>72,102</sup>

Clinicians must know their community and the resources available within their catchment area to better facilitate seamless transition across sectors (e.g., from hospital to home, or home to respite). Establishing a culture of respect is the responsibility of all stakeholders, including every member of the interprofessional team, the patient and the patient’s support network, which may include the family or caregiver/care partner.<sup>103</sup>

### 3.2 Enlist the patient and their family and caregivers as part of the team

Patient participation is shown to increase positive patient outcomes and experience within health-care systems.<sup>103</sup> As well, including the patient in their own plan of care can empower them, resulting in better overall health and building relationships with the health-care providers.<sup>82,104,105</sup> Clinicians must therefore initiate the conversation about self-managed MASD care at the initial interaction to promote independence and encourage patients to actively participate in their care. The team must then define roles for each member (see Table 7). Next, the team should collaboratively establish expectations from each member to ensure engagement and co-ordination of all activities related to MASD prevention or management. To be a contributing member and to optimize outcomes, the patient and their care partners must fully understand their health-related conditions and all components of the plan of care. A well-functioning team with the patient at the centre increases the likelihood of successful engagement. This can result in higher patient satisfaction and QoL, greater comprehension of personal requirements, more informed decision-making ability, reduced anxiety and emotional turmoil, a stronger bond among members of the team and higher rates of healing.<sup>104,105</sup>

**Table 7:** Professional Members of the Team

Discipline	Roles and Responsibilities for Wound Healing (these may vary depending on health-care setting)
<b>Wound care clinician (nurse with advanced wound, ostomy education)</b>	<ul style="list-style-type: none"> <li>• Performs comprehensive assessment to determine the source of moisture and optimize care planning to manage and prevent complications<sup>50</sup></li> <li>• Advocates for publicly funded sources, when required</li> <li>• Facilitates knowledge transfer to patients, care partners, families and health-care providers (care coordination, case management)</li> <li>• Provides leadership by promoting best practice<sup>50,106,107</sup></li> </ul>
<b>Physician or nurse practitioner (NP)</b>	<ul style="list-style-type: none"> <li>• Coordinates care, including management of existing health conditions</li> <li>• Provides necessary prescriptions to alleviate symptoms of MASD, such as fungal infections, restoration of skin barrier function and inflammation</li> <li>• Treats coexisting skin conditions such as eczema or psoriasis</li> </ul>
<b>Registered dietitian (RD)</b> <b>See Appendix: Nutrition for Skin Health, Wound Prevention and Wound Healing in Chapter 4: Best Practice Recommendations for the Prevention and Management of Wounds: An Overview<sup>49</sup></b>	<ul style="list-style-type: none"> <li>• Provides a nutrition assessment to ensure patients are consuming adequate amounts of micro/macro nutrients to support skin integrity and synthesis of healthy tissue<sup>50</sup></li> <li>• Supports optimal nutrition for those at risk of dehydration and malnutrition, such as high output ileostomies and those losing excess fluid (e.g., diarrhea, vomiting)<sup>50</sup></li> <li>• Maximizes nutrient intake for those with poor appetite or intake to meet increased nutrient needs required for wound healing</li> <li>• Provides nutritional counselling to people with obesity, malnutrition, diabetes and other chronic diseases that impact skin integrity</li> </ul>

<b>Personal support worker/care aid workers</b>	<ul style="list-style-type: none"> <li>• Provides day-to-day care of the patient</li> <li>• Identifies and reports MASD at onset<sup>108</sup></li> </ul>
<b>Occupational therapist (OT)</b>	<ul style="list-style-type: none"> <li>• Performs cognitive and psychosocial assessment and provides interventions</li> <li>• Ensures assessment and management of appropriate equipment to support functional continence<sup>50</sup></li> <li>• Performs a surface assessment as certain mattresses increase moisture (e.g., low air loss when a fitted sheet is used). This example can also increase the risk of dehydration, demonstrating the importance of having the whole team assess and plan together</li> <li>• Assesses ability to self-care and provide tools to help maintain autonomy and activities of daily living within the home</li> </ul>
<b>Physiotherapist (PT)</b>	<ul style="list-style-type: none"> <li>• Assesses the strength and ability to contract and relax the pelvic floor muscles. This is performed by physiotherapists with additional education in pelvic floor management<sup>50</sup></li> <li>• Teaches strength-building exercises to avoid muscle wasting, as patients may limit their mobility to avoid episodes of leakage or incontinence; validates if pelvic floor exercises are correctly executed to determine effectiveness<sup>50</sup></li> </ul>
<b>Pharmacist</b>	<ul style="list-style-type: none"> <li>• Reviews all medications to avoid possible interactions with any topical products being used, identifies any medications that may impact the ability to heal and/or provides alternative medication choices to increase adherence<sup>109</sup></li> <li>• Provides recommendations on a variety of continence-related medications such as diuretics, stool softeners and laxatives</li> <li>• Collaborates with dietitian, as needed, when recommending vitamins, minerals and/or supplements</li> </ul>
<b>Social worker (SW)</b>	<ul style="list-style-type: none"> <li>• Reviews and/or performs cognitive and psychosocial assessment and provides interventions</li> <li>• Ensures care coordination and transitions of care</li> <li>• Determines any financial or social supports needed (e.g., devices, funding for products)</li> </ul>
<b>Psychologist</b>	<ul style="list-style-type: none"> <li>• Provides a psychosocial assessment</li> <li>• Offers interventions</li> </ul>

### 3.3 Ensure organizational and system support

Individuals with MASD experience a significant decrease in QoL and are more prone to PIs and secondary skin infections, which may in turn be associated with increased financial costs to the health-care system.<sup>11,110</sup>

Organizational acknowledgement of risk factors and implementation of prevention strategies for the various types of MASD are crucial to prevent occurrence. Awareness, access and appropriate evidence-based implementation of products among all members of the team are necessary to control the various sources of moisture for any type of MASD and reduce negative outcomes in any health organization, public or private.

The World Health Organization recognizes MASD as a significant cause of skin injury and has included types of MASD in the latest version of the International Classification of Diseases.<sup>111</sup> This global attention can ultimately foster increased recognition among clinicians at a systems level regarding accurate identification and reporting, treatment goals, management and prevention strategies for MASD.<sup>21</sup>

Additionally, Kayser et al. examined the prevalence and risk factors of IAD within adult patients in LTC, acute care and rehabilitation facilities in both Canada and the US. They noted nearly 1 in 5 incontinent patients had documented IAD. Of the incontinent patients, prevalence of IAD ranged from 8.4% in LTC facilities to 19% in acute care facilities. This study demonstrates the significant burden of IAD on both the patient population and the health-care system.<sup>26</sup>

Organizations, in collaboration with the health-care team, can include a toileting schedule for those admitted with mobility issues to reduce the likelihood of complications associated with incontinence. Costs associated with prevention strategies are likely to be far less than those associated with managing the resulting skin damage. With the increasing complexity of patients combined with ongoing staff shortages, it is no wonder the proportion of nurses reporting that they miss skin care in their regular routine of patient care is as high as 39.5%.<sup>112</sup> System support requires organizations to provide adequate staffing to ensure such vital prevention strategies are not missed.

## Step 4: Establish and Implement a Plan of Care

### 4.1 Identify and implement an evidence-informed plan to maintain skin health and correct the causes or co-factors that affect skin integrity, including patient needs (physical, emotional and social), the wound (if applicable) and environmental/system challenges

Once the origin of risk or actual MASD has been identified, implement steps to reduce the presence of moisture to protect skin integrity, and support the wound healing process. Preventing and correcting the cause for all types of MASD includes removing the moisture source or, at a minimum, reducing the length of exposure time of the epidermis to the moisture source. Repairing the epidermal barrier with emollients and humectants and using appropriate products such as skin barriers and dressings to manage the moisture source are essential evidence-based strategies to include in each plan of care.<sup>23,34,113</sup>

In cases of recalcitrant MASD, percutaneous testing may be necessary to look for potential allergic contact dermatitis.<sup>114</sup> Sources of contact allergens include topical antibiotics, preservatives, antioxidants and fragrances in skin cleansers, emollients and barrier creams. Components of the dressings themselves may act as allergens.<sup>115,116</sup> Testing for contact allergy may require a referral to a specialized clinic/service (i.e., dermatologist).<sup>117</sup>

Clinicians should always assess and manage emotional, social and psychological factors associated with MASD.<sup>80,81</sup>

MASD necessitates continuing commitment from the clinician to recognize and care for patients.<sup>110</sup> Disciplines and facilities must engage in best practice interventions for both prevention and treatment of MASD which also extends to standardized documentation.<sup>110</sup>

Peristomal skin complications are very specific and require the advice of experts. Consultation by a stoma care nurse or nurse specialized in Wound, Ostomy and Continence (NSWOC) is often required to reduce the risk of complications. See Table 8 for prevention and management strategies for MASD.

**Table 8:** Prevention and Management Strategies

Type of MASD	Prevention and Treatment Strategies
<b>IAD</b>	<ul style="list-style-type: none"> <li>• Assess and treat reversible causes of incontinence<sup>50</sup></li> <li>• Put in place a skin care regimen and ensure all team members are diligent with the plan</li> <li>• Optimize nutrition/fluid management<sup>50</sup></li> <li>• Provide appropriate containment devices/products and ensure they are applied correctly</li> <li>• Check containment products on a regular basis</li> <li>• Ensure prompt and frequent changes of soiled products and cleanse and protect the skin adequately</li> <li>• Facilitate purchase of highly breathable and absorbent product, ensuring correct fit<sup>118</sup></li> <li>• Introduce toileting techniques as able, including appropriate equipment, devices and education</li> </ul>

<b>ITD</b>	<ul style="list-style-type: none"> <li>• Apply moisture-wicking product impregnated with silver<sup>61</sup> or PHMB-impregnated gauze between the folds to wick away or absorb moisture (follow manufacturers product supply information)</li> <li>• Select clothing that is loose-fitting and breathable, such as cotton</li> <li>• Make sure antifungal cream or oral antifungal treatment is continued for 7 days after the disappearance of clinical signs to prevent recurrence.</li> <li>• Administer pain and antihistamine medication according to pain and discomfort assessment</li> <li>• Reduce or eliminate skin-on-skin contact<sup>61</sup></li> <li>• Encourage, where able, weight reduction in case of obesity.</li> <li>• Instruct patient and care partners on the importance of bathing, showering (especially after exercise) and carefully drying skin folds</li> </ul>
<b>Periwound MASD</b>	<ul style="list-style-type: none"> <li>• Use appropriate dressing types to manage moisture balance (See Wounds Canada’s <a href="#">Wound Dressing Selection Guide</a>)</li> <li>• Apply a skin protectant (no-sting film barrier, petrolatum-based or zinc-based skin protectant) to the periwound skin to reduce the risk of periwound skin maceration<sup>119</sup></li> </ul>
<b>Peristomal MASD</b>	<p>GI/GU Ostomy:</p> <ul style="list-style-type: none"> <li>• Maintaining skin integrity relies on proper selection, application and function of ostomy products and skin barrier appliances, for adequate protection</li> <li>• Use appropriate technique and ostomy devices to provide a good seal</li> </ul> <p>Tracheostomy:</p> <ul style="list-style-type: none"> <li>• Keep peristomal skin dry, and apply absorbent products that will keep the humidity away from the skin and absorb any leakage<sup>120</sup></li> <li>• Apply a moisture-wicking product impregnated with silver<sup>61</sup> or PHMB-impregnated gauze</li> <li>• Consider referral to a respiratory therapist and consider non-product-based treatment such as increasing frequency of upper airway suction</li> </ul> <p>Gastrostomy:</p> <ul style="list-style-type: none"> <li>• Identify and correct the cause of leakage</li> <li>• Keep peristomal skin dry and apply absorbent products that will keep the humidity away from the skin and to absorb any leakage<sup>120</sup></li> <li>• Consider referral to NSWOC, stoma or gastroenterology nurse<sup>121</sup></li> </ul>
<b>Immersion Foot (IF)</b>	<ul style="list-style-type: none"> <li>• Address physical and mental status and consider social assessment during acute events</li> <li>• Provide first aid to severely affected individuals by following the same treatment protocols for frostbite<sup>39-41</sup></li> </ul>
<b>Frostbite*</b>	<ul style="list-style-type: none"> <li>• Educate patients to prevent repeat injury<sup>39-41</sup></li> </ul>

\* For frostbite see [Chapter 8: Best Practice Recommendations for the Prevention and Management of Burns](#).

Canadian health-care professionals and individuals can contact Nurses Specialized in Wound, Ostomy and Continence Canada (NSWOCC) to find a stoma, wound, continence care specialist in their area.

#### 4.2 Optimize the local wound environment

The first step in treating any form of MASD is to control the moisture on the affected skin and prevent the moisture from accumulating and lingering. Management strategies for MASD are outlined in Table 9.

**Table 9:** Skin and Wound Management for MASD

	IAD	ITD	Periwound MASD	Peristomal MASD	IF
<b>4.2.1 Cleansing</b> <small>17, 21,22,122,123</small>	<p>Wash with a gentle cleanser* (avoid soap or alkaline products)</p> <p>Cleanse the surrounding intact skin well</p> <p>Pat dry; do not rub</p> <p>Single-use wash cloths are preferred</p> <p>Use no-rinse skin cleansers</p>	<p>Use a noncytotoxic agent* (typically potable water, normal saline irrigating solution or an appropriate wound-cleaning agent)</p> <p>Cleanse the surrounding intact skin well</p> <p>Pat dry; do not rub</p>	<p>Use a noncytotoxic agent* (typically potable water, normal saline irrigating solution or an appropriate wound-cleaning agent, neutral pH between 6.5 to 7.5)</p> <p>Cleanse the surrounding intact skin well, 10-20 cm outward from the damaged skin edge</p> <p>Pat dry; do not rub</p>	<p>Wash with potable water.</p> <p>Use a soft or disposable cloth.</p> <p>Gently but thoroughly pat dry</p> <p>Avoid soaps (especially oily soaps) and other alkaline products</p>	<p>Use a noncytotoxic agent* (typically potable water, normal saline irrigating solution or an appropriate wound-cleaning agent)</p> <p>Cleanse the surrounding intact skin</p> <p>Pat dry, do not rub</p>
<b>4.2.2 Debriding</b>	No	No	No	No	Yes, if indicated by the presence of necrotic tissue and adequate blood flow
<b>4.2.3 Managing bacterial balance</b> <small>17,21, 22,122-123</small>	<p>Category 1B where fungal (link to note below) infection is evident, apply a miconazole-containing paste 1-2 times daily</p> <p>Category 2B, where signs for increased bioburden is evident, a swab should be done</p>	<p>Place silver-impregnated fabric between the folds to wick away moisture</p> <p>Use PHMB-impregnated gauze</p> <p>Antiperspirant, loose clothing, good air flow</p>	<p>Ensure periwound hygiene and protection</p>	<p>Apply antifungal cream or powder in case of fungal infection. Apply for 7 days after the disappearance of the clinical signs of fungal infection</p> <p>When applying cream, ensure the cream is well penetrated before applying the ostomy pouching system</p>	<p>Prophylactic antibiotics have no benefit; however, if infection is suspected, target streptococcal, staphylococcal and <i>Pseudomonas aeruginosa</i></p>

**Note:** Fungal infections: When a fungal infection is diagnosed, apply an antifungal cream/product as prescribed (usually 2-3 times a day). However, in the case of IAD, it is important to apply a skin barrier cream over the antifungal product to protect the skin from stools and urine. The skin barrier should be applied as many times as needed.

<p><b>4.2.4 Managing moisture balance</b><sup>17,21 22, 122,123</sup></p>	<p>Use polymer-based incontinence products or under pads instead of non-polymer</p> <p>In the case of extensive diarrhea, it is preferable to apply pads instead of briefs</p> <p>When applied, briefs should not be closed tightly</p> <p>Use containment devices when appropriate<sup>4</sup></p>	<p>Place silver-impregnated fabric between the folds to wick away moisture</p> <p>Apply PHMB impregnated gauze</p>	<p>Use a cover dressing** designed to absorb the exudate vertically to protect the periwound skin or absorbent enough to avoid any leaking on intact skin</p> <p>Use absorbent dressings such as alginate, gelling fibre, polymers and foam</p> <p>Protect the skin with no-sting barrier film or ointment-based skin protectant. Explore the form and function of various products to ensure maximal absorption and skin protection (e.g., not all foam dressings will absorb and lock exudate away from periwound skin)</p>	<p>Ensure the ostomy skin barrier is protecting the peristomal skin<sup>121</sup></p> <p>Assess pouching device to ensure proper fit and prevention of leakage</p>	<p>N/A</p>
---	---	--	---	--	------------

<b>4.3 Select appropriate care or therapy</b> <sup>17, 21, 22, 122-123</sup>	Hydrophillic paste dressings	Moisture-reduction products (4.2.3)	Apply a non-alcohol-based (or no sting) liquid skin protectant to the periwound skin	Refer to a wound care clinician or a stoma care nurse	Provide adequate oral analgesia (e.g., amitriptyline; however, this is still not well supported)
	Petrolatum, zinc or dimethicone-based barrier ointments or creams	Treat infection by lightly dusting skin with antifungal powder	Apply barrier creams	Consider referral to a dermatologist for recalcitrant dermatitis	Elevate affected extremity
	No-sting film barrier or ointment	Use of anti-inflammatory topical steroids when needed (in case of major inflammation), for a limited period	Control moisture with appropriate absorptive dressings, ideally providing vertical absorption		Hypothermic cooling
	In the case of fungal infection, avoid use of no-sting film barrier until the infection is resolved	Consider referral to a dermatologist for recalcitrant dermatitis	In some cases, excessive moisture may be due to edema, which must be controlled (such as using compression in venous leg ulcers and lymphedema)		Slow rewarming
	Implement a personalized toileting schedule				Pain relief
	If using containment products, ensure that barrier products are compatible with the containment device				

\*See *Product Picker for Skin and Wound Clean-up* <https://www.woundscanada.ca/dhfy-doc-man/public/health-care-professional/1307-product-picker-skin-and-wound-clean-ip>

\*\*See *Product Picker for Dressing Selection* <https://www.woundscanada.ca/docman/public/health-care-professional/1114-product-picker-2017-selection-guide-1/file>

### 4.3 Select the appropriate dressings and/or advanced therapy

**IAD:** Liquid film-forming acrylate sprays or wipes can provide an adequate barrier in instances with occasional incontinence. Ointments with a petrolatum, zinc oxide or dimethicone based are commonly reported to be effective and inexpensive barriers; cream-based products, however, are more likely to promote hydration in addition to providing a barrier. Containment devices may be required when severe incontinence is not well-managed using barrier films. Ensure that any barrier products used are compatible with the selected containment device. Successful prevention and treatment of IAD are dependent upon three strategies: the removal of feces and/or urine from the affected skin; the application of a moisturizer to repair skin barrier function; and the use of a barrier, usually in the form of cream, to prevent further damage to the epidermis from feces and urine.<sup>70</sup>



Utilize the ACT mnemonic (Assess, Cleanse, Treat). Steps to preventing and treating the cause of IAD includes, as a method of prevention, assessing those not yet experiencing skin breakdown:

**Step 1:** Assess the skin after each episode of incontinence to determine the irritant and note the condition of skin.

**Step 2:** Cleanse using pH-balanced solution, protect the skin and contain the effluent.

**Step 3:** Treat vulnerable, damaged, traumatized skin<sup>123</sup>

There is a role for using topical corticosteroids to reduce inflammation until moisture balance is achieved. Plan use with the primary care provider and pharmacist and monitor for skin improvement. Care is required, however, to avoid epidermal atrophy from inappropriate topical corticosteroid use, especially if the steroid is used under occlusive products such as dressings and barriers.<sup>124</sup>

**ITD:** Initial treatment must always include managing underlying factors. It is crucial to rule out any secondary infection prior to proceeding with a plan of care. It is also imperative that other skin conditions be ruled out.<sup>21,24</sup> Methods of preventing moisture build-up include the use of antiperspirants, wearing loose clothing to avoid overheating, and trying to remain in air-conditioned places.<sup>21,24</sup>

Treatment of intertrigo is dependent on reducing or removing the predisposing cofactors of heat, humidity and infection where present. Dressing choice is often difficult, as affected areas are frequently compounded by hard-to-dress locations and, in ambulatory patients, physical movement. Barrier creams, zinc or talc solutions and powders are of limited value; however, these products may be considered for recalcitrant cases.<sup>33</sup> Other successful management strategies include placing a piece of textile with embedded wicking fabrics in the skin fold to draw moisture away from the apex of the fold, thereby reducing the amount of moisture within the area; however, the effectiveness of this intervention remains unknown.<sup>24</sup>

There is often a role for targeting the overgrowth of yeast organisms with topical antifungal therapy. A variety of topical antifungal agents are used to combat fungal infections of the skin, including polyene antifungals, such as nystatin; azole-type antifungals, such as clotrimazole, econazole and ketoconazole, and allylamine antifungals, such as terbinafine, most of which can be applied twice daily for 10 to 14 days. Low-dose topical corticosteroids may also be used in combination with an antifungal to reduce epidermal inflammation and speed restoration of normal skin barrier function.<sup>24</sup>

**Periwound MASD:** This occurs when wound exudate (mild to copious) comes into contact with skin (short or longer durations). The proteolytic enzymes erode the skin's ability to remain intact. Chronic wounds have increased enzyme levels and when in contact with the skin, are more likely to cause periwound MASD.<sup>125</sup> Irritation and pruritus may cause the patient to scratch their skin, leading to secondary infections and further skin irritation/injury.

Signs of periwound MASD include erythema, maceration and skin loss. Macerated skin is soggy and soft, and it may be whiter than usual. Among darker-skinned patients, maceration presents as gray-white and wrinkled skin. Effective treatment uses a two-pronged approach aimed at reducing the moisture on the skin and repairing skin barrier function.<sup>119</sup>

**Peristomal MASD:** Treatment and management of peristomal MASD can be difficult, because any investigation of dermatitis under an appliance must first consider etiologic factors. Treatment should always involve a wound care clinician/stoma nurse with advanced knowledge.<sup>121</sup> Film skin protectants may not be appropriate for application under an ostomy appliance, because many of the barriers are intended to adhere to dry intact skin.<sup>126</sup> Therefore, it is essential to determine the source of moisture, most often leakage, and find a method to control it. For extreme inflammation, a dermatologist should be consulted for additional steroid therapy. Overuse of a corticosteroid, however, can be damaging to the skin long-term, and follow-up skin assessment by a specialist in this area is recommended.

The selection of a barrier (e.g., an antimicrobial containing fabric) to be applied around a tracheostomy site should be based on the ability of the barrier to keep the surrounding skin dry and intact. This includes ease of application and removal, but any barrier should be used with caution to prevent obstruction.<sup>127</sup>

**Immersion Foot (IF):** Less severe forms of IF (uncomplicated by ischemic injury or infection) should be managed with the conservative measures of drying feet, applying a barrier cream and the use of appropriate analgesics.<sup>128</sup> Evidence suggests, however, that some patients may experience a persistent vaso-neuropathy, even after resolution of the cutaneous findings, resulting in pain and/or persistent sensory abnormalities as demonstrated on Semmes-Weinstein and thermal testing.<sup>129</sup> Prevention of reinjury can be accomplished by keeping the feet warm and dry with daily application of a barrier cream, ensuring the wearing of adequate footwear/dry socks and use of appropriate analgesics if required.<sup>40,41</sup> Treatment of severe injury is best achieved by slow rewarming of the affected limb(s) to prevent reperfusion injury.

This is of importance for persons experiencing homelessness. Those, without adequate shelter or housing need support to obtain and maintain adequate foot hygiene practices, as well as properly fitting shoes for various weather conditions.<sup>130</sup>

Products *not* recommended for MASD are those that donate moisture to the area such as hydrogels or dressings promoting an occlusive environment, thereby restricting moisture evaporation.

#### **4.4 Engage the team to ensure consistent implementation of the plan of care**

To optimize the outcome, it is essential to engage all members of the integrated team in care planning and implementation. For nursing staff, education and awareness campaigns that report the outcomes of MASD prevention strategies help change practice. Keeping the patient and family members engaged is crucial, as the patient will ultimately control many of the underlying factors that caused the MASD.

### **Step 5: Evaluate Outcomes**

#### **5.1 Determine if the outcomes have met the goals of care**

Reassessment of MASD helps clinicians determine if prevention and treatment plans have achieved the established goals. If a clinician implements a routine skin care regimen, an improvement should be noted within a two-week period.<sup>131</sup> If subtypes of MASD are not resolving and skin integrity is not maintained, it is necessary to reassess causative factors and barriers to healing and revise the care plan.

#### **5.2 Reassess patient, wound, environment and system if goals partially met or unmet**

If the goals are only partially met or unmet, complete a systematic assessment to re-evaluate the goals and determine the reasons for unsuccessful prevention and management of MASD. Including team members is important in reassessing and exploring modifiable factors, patient involvement and patient ability to support the care plan. Erythema, maceration, erosion, related pain and patient satisfaction are crucial factors in considering outcomes for MASD secondary to IAD.<sup>17</sup> Additional important outcomes for consideration are colonization and infection of MASD and the impact of MASD on the patient's quality of life. Less-experienced clinicians should discuss with the appropriate team members or other mentors to confirm the subtype of MASD. Other skin conditions, such as cutaneous fungal infections, dermatitis, bacterial infection and PI, should be ruled out in the assessment process.<sup>21</sup>

Timely referral and continued use of categorization and assessment tools can provide a foundation for development of validated assessment tools able to reliably detect change.

#### **Patient Reassessment**

The literature indicates that individuals with bladder and bowel incontinence are more likely to develop a PI than those who are not incontinent. Pressure injury should be assessed in unresolved MASD, by appropriate clinicians, and prevention strategies implemented. Frequent skin assessments are required, and a bundled approach to care should be implemented if it is deemed that an individual is at risk of MASD and PIs.<sup>70,132</sup> Clinicians should also reassess mobility, overall nutrition, continence status and possible allergies.<sup>31</sup>

### 5.3 Ensure sustainability to support prevention and reduce risk of recurrence

Identifying and managing the cause of the MASD, type of MASD and patient barriers to healing are vital in reducing risk of recurrence. Incorporating prevention strategies into the plan of care can promote preventative behaviour throughout the management process.

#### Routine and Structured Skin Care Regimen

Implementation of a consistent and structured skin care regimen is essential for preventing and managing MASD. Education for patients, families and care partners regarding the skin care regimen is important for sustaining and reducing recurrence rates.

#### Social Isolation and Depression

The impact of MASD on the patient's psychological and social functioning is also an important consideration. Social isolation and loss of independence can lead to depression, something clinicians should be prepared to assess and manage. This includes ongoing evaluation and education of patients and families, including care partner education.<sup>59,70</sup>

#### Environment

Assessment of an individual's environment is crucial to determine whether there is appropriate equipment, capacity to participate in self-care, and if the home is conducive to good hygiene practices. Knowledge of community resources (e.g., pharmacies within close proximity, access to food and medical supply stores, community supports) is helpful in supporting the patient to remain at home.

#### Cost Effectiveness

If risk factors for MASD are not well managed, individuals, care partners and health-care systems will experience increased costs. Health-care professionals and individuals need to be aware of the various products available.<sup>21</sup> Guides, such as the Wound, Ostomy and Continence Nurses' (WOCN) *Body Worn Absorbent Product Guide*, are valuable in assisting health-care professionals with such decision-making. Wounds Canada's Do-It-Yourself Series: *Incontinence-associated dermatitis (IAD)* and *Intertrigo* are valuable resources for patients, care partners, and clinicians. <https://www.woundscanada.ca/patient-or-caregiver/resources/diy-series>

The greater health-care system should consider the entire cost of care and clinical outcomes when making decisions about publicly funded formularies and compendiums. Often the focus is on the hard cost of products versus the larger picture. For nosocomial-related MASD, organizations should not hold the patient accountable for funding their own products to manage situations caused by inadequate health-care resources. This is often the case post discharge, when the patient returns home.

### Conclusion

The Wound Prevention and Management Cycle ensures the patient remains the focus of care and helps the clinician navigate through a comprehensive assessment and plan of care. It is critical to promptly recognize any emerging clinical signs of MASD and understand the differences among these types in order to make the right diagnosis. Taking the time to complete a holistic head-to-toe patient assessment will help to unveil underlying factors and aid in determining the type of MASD. This, in turn, enables the clinician to develop an appropriate health-care team and put in place an effective plan for prevention or care.

In all patients, supported self-care should be encouraged wherever possible, with the individual encouraged to engage with their treatment and be educated about the importance of skin integrity and protection. Individual capacity will need to be considered so that the appropriate level of ability and willingness to be involved can be ascertained. All self-care should be encouraged within a support system and the patient must know how to obtain

further advice when needed.<sup>16</sup> It is crucial for all team members to adhere to a standardized approach to ensure the continuity of care that is the key to obtaining positive outcomes. Regular, ongoing education about MASD is strongly recommended. Nundy et al. recommend teams focus on the quintuple aim, including data collection and research initiatives that support and seek health care improvement. This includes focusing on understanding the patient and care partner experiences, exploring ways to reduce costs, improving population health, improving the clinician experience and enhancing equity.<sup>47</sup>

## References

- Gray M, Bliss DZ, McNichol L. Moisture-associated skin damage: expanding and updating practice based on the newest ICD-10-CM codes. *J Wound Ostomy Continence Nurs.* 2022 Mar-Apr 01;49(2):143-151. DOI: 10.1097/WON.0000000000000865
- Black JM, Gray M, Bliss DZ, Kennedy-Evans KL, Logan S, Baharestani MM, et al. MASD part 2: incontinence-associated dermatitis and intertriginous dermatitis: a consensus. *J Wound Ostomy Continence Nurs.* 2011 Jul-Aug;38(4):359-70. DOI: 10.1097/WON.0b013e31822272d9
- Voegeli D. Moisture-associated skin damage: aetiology, prevention and treatment. *Br J Nurs.* 2012 May 10-23;21(9):517-8, 520-1. DOI: 10.12968/bjon.2012.21.9.517
- Woodward S. Moisture-associated skin damage: use of a skin protectant containing manuka honey. *Br J Nurs.* 2019 Mar 28;28(6):329-335. DOI: 10.12968/bjon.2019.28.6.329
- Bender JK, Faergemann J, Sköld M. skin health connected to the use of absorbent hygiene products: a review. *Dermatol Ther (Heidelb).* 2017 Sep;7(3):319-330. DOI: 10.1007/s13555-017-0189-y
- Collier M, Simon D. Protecting vulnerable skin from moisture-associated skin damage. *Br J Nurs.* 2016 Nov 10;25. DOI: 10.12968/bjon.2016.25.20.526
- Lumbers M. Caring for and cleansing a baby's skin. *Br J Nurs.* 2018 Feb 8;27(3):148-151. DOI: 10.12968/bjon.2018.27.3.148
- Bernard L, Stephens M, Kuhnke JL. Prevention of incontinence associated dermatitis associated with brief use in acute care: a quality improvement project. *NSWOC Advance.* 202 Sep;(31):2:28-37. Available from: <https://go.gale.com/ps/i.do?id=GALE%7CA672224291&sid=sitemap&v=2.1&it=r&p=AONE&sw=w&userGroupName=anon%7E5915b0d&aty=open-web-entry>
- Baranoski S, Ayello EA. *Wound care essentials: practice principles.* Philadelphia: Lippincott Williams & Wilkins; 2008.
- World Health Organization. *International classification of diseases 11th revision.* 2023. Available from: <https://icd.who.int/en>
- Gray M, Colwell JC, Doughty D, Goldberg M, Hoeflok J, Manson A, et al. Peristomal moisture-associated skin damage in adults with fecal ostomies: a comprehensive review and consensus. *J Wound Ostomy Continence Nurs.* 2013 Jul-Aug;40(4):389-99. DOI: 10.1097/WON.0b013e3182944340
- Voegeli D. Prevention and management of moisture-associated skin damage. *Nurs Stand.* 2019 Jan 25;34(2):77-82. DOI: 10.7748/ns.2019.e11314
- Das A, Kumar S, Sil A, Jafferany M. Skin changes attributed to protective measures against COVID-19: A compilation. *Dermatol Ther.* 2020 Jul;33(4):e13796. DOI: 10.1111/dth.13796
- Atkinson K, Lodge L, Todd C, Lawson H, Smyth S. Seven aetiologies of MASD: devising a protocol for improved care. *Journal of Community Nursing.* 2022 Feb 1;36(1). Available from: <https://openurl.ebsco.com/EPDB%3Agcd%3A14%3A11138046/detailv2?sid=ebsco%3Aplink%3Ascholar&id=ebsco%3Agcd%3A155145812&crl=c>
- Mitchell A, Hill B. Moisture-associated skin damage: an overview of its diagnosis and management. *Br J Community Nurs.* 2020 Mar 1;25(3):S12-S18. DOI: 10.12968/bjcn.2020.25.Sup3.S12
- Fletcher J, Beeckman D, Boyles A, Furnarola S, Kottner J, McNichol L et al. Prevention and management of moisture-associated skin damage (MASD). *Wounds International;* 2020. Available from: [https://multimedia.3m.com/mws/media/21556090/3m-masd-wounds-international-recommendation-us-version.pdf?utm\\_term=hcbg-msd-icuroh-en\\_us-eng-icu\\_cwc-osm-lin-na-dwln-masdpost1-dec22-00000](https://multimedia.3m.com/mws/media/21556090/3m-masd-wounds-international-recommendation-us-version.pdf?utm_term=hcbg-msd-icuroh-en_us-eng-icu_cwc-osm-lin-na-dwln-masdpost1-dec22-00000)
- Woo KY, Beeckman D, Chakravarthy D. Management of moisture-associated skin damage: a scoping review. *Adv Skin Wound Care.* 2017 Nov;30(11):494-501. DOI: 10.1097/01.ASW.0000525627.54569.da
- Werth SL, Justice R. Prevalence of moisture-associated skin damage in an acute care setting: outcomes from a quality improvement project. *J Wound Ostomy Continence Nurs.* 2019 Jan/Feb;46(1):51-54. DOI: 10.1097/WON.0000000000000499
- Bliss DZ, Mathiason MA, Gurvich O, Savik K, Eberly LE, Fisher J, et al. Incidence and predictors of incontinence-associated skin damage in nursing home residents with new-onset incontinence. *J Wound Ostomy Continence Nurs.* 2017 Mar/Apr;44(2):165-171. DOI: 10.1097/WON.0000000000000313
- Dissemond J, Assenheimer B, Gerber V, Hintner M, Puntigam MJ, Kolbig N, et al. Moisture-associated skin damage (MASD): a best practice recommendation from Wund-D.A.CH. *J Dtsch Dermatol Ges.* 2021 Jun;19(6):815-825. DOI: 10.1111/ddg.14388
- Gray M, Bliss DZ, McNichol L. Moisture-Associated Skin Damage: Expanding and Updating Practice Based on the Newest ICD-10-CM Codes. *J Wound Ostomy Continence Nurs.* 2022 Mar-Apr 01;49(2):143-151. DOI: 10.1097/WON.0000000000000865
- Beele H, Smet S, Van Damme N, Beeckman D. Incontinence-associated dermatitis: pathogenesis, contributing factors, prevention and management options. *Drugs Aging.* 2018 Jan;35(1):1-10. DOI: 10.1007/s40266-017-0507-1
- Young T. Back to basics: understanding moisture-associated skin damage. *Wounds UK.* 2017 Nov 1;13(2):56-65. Available from: <https://wounds-uk.com/journal-articles/back-basics-understanding-moisture-associated-skin-damage/>
- Nobles T, Miller RA. Intertrigo. *StatsPearls.* 2022 Sep 19. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK531489/>
- Kayser SA, Koloms K, Murray A, Khawar W, Gray M. Incontinence and incontinence-associated dermatitis in acute care: a retrospective analysis of total cost of care and patient outcomes from the premier healthcare database. *J Wound Ostomy Continence Nurs.* 2021 Nov-Dec 01;48(6):545-552. DOI: 10.1097/WON.0000000000000818
- Kayser SA, Phipps L, VanGilder CA, Lachenbruch C. Examining prevalence and risk factors of incontinence-associated dermatitis using the international pressure ulcer prevalence survey. *J Wound Ostomy Continence Nurs.* 2019 Jul/Aug;46(4):285-290. DOI: 10.1097/WON.0000000000000548
- Babino G, Argenziano G. Incontinence-associated dermatitis: an insidious and painful condition. In: Docimo L, Bruscianno L, editors. *Anal incontinence: clinical management and surgical techniques.* Springer Cham; 2023. 179-87. Available from: 10.1007/978-3-031-08392-1\_21

28. Rodríguez-Palma M, Verdú-Soriano J, Soldevilla-Agreda JJ, Pancorbo-Hidalgo PL, García-Fernández FP. Conceptual framework for incontinence-associated dermatitis based on scoping review and expert consensus process. *J Wound Ostomy Continence Nurs.* 2021 May-Jun 01;48(3):239-250. DOI: 10.1097/WON.0000000000000754
29. Nazarko L. Intertrigo: a guide to diagnosis, treatment and prevention. *British Journal of Healthcare Assistants.* 2018 Oct 2;12(10):479-85. DOI: 10.12968/bjha.2018.12.10.479
30. Voegeli D. Intertrigo: causes, prevention and management. *Br J Nurs.* 2020 Jun 25;29(12):S16-S22. DOI: 10.12968/bjon.2020.29.12.S16
31. Dowsett, C, Allen, L. Moisture-associated skin damage made easy. *Wounds UK.* 2013 Nov;9(4):1-4. Available from: <https://www.cambscommunityservices.nhs.uk/docs/default-source/luton-tissue-viability/masd/masd-made-easy.pdf?sfvrsn=2>
32. Parnham A, Copson D, Loban T. Moisture-associated skin damage: causes and an overview of assessment, classification and management. *Br J Nurs.* 2020 Jun 25;29(12):S30-S37. DOI: 10.12968/bjon.2020.29.12.S30
33. Metin A, Dilek N, Bilgili SG. Recurrent candidal intertrigo: challenges and solutions. *Clin Cosmet Investig Dermatol.* 2018 Apr 17;11:175-185. DOI: 10.2147/CCID.S127841
34. Colwell JC, Ratliff CR, Goldberg M, Baharestani MM, Bliss DZ, Gray M, et al. MASD part 3: peristomal moisture-associated dermatitis and periwound moisture-associated dermatitis: a consensus. *J Wound Ostomy Continence Nurs.* 2011 Sep-Oct;38(5):541-53. DOI: 10.1097/WON.0b013e31822acd95
35. Herlufsen P, Olsen AG, Carlsen B, Nybaek H, Karlsmark T, Laursen TN, et al. Study of peristomal skin disorders in patients with permanent stomas. *Br J Nurs.* 2006 Sep 14-27;15(16):854-62. DOI: 10.12968/bjon.2006.15.16.21848
36. John B, Kim MY, Kelly D. Risk factors associated with peristomal skin complications: integrative literature. *World Council of Enterostomal Therapists Journal.* 2018 Apr 1;38(2). Available from: <https://openurl.ebsco.com/EPDB%3Agcd%3A6%3A21152966/detailv2?sid=ebsco%3Aplink%3Ascholar&id=ebsco%3Agcd%3A130265578&crl=c>
37. Taneja C, Netsch D, Rolstad BS, Inglese G, Lamerato L, Oster G. Clinical and economic burden of peristomal skin complications in patients with recent ostomies. *J Wound Ostomy Continence Nurs.* 2017 Jul/Aug;44(4):350-357. DOI: 10.1097/WON.0000000000000339
38. Nagano M, Ogata Y, Ikeda M, Tsukada K, Tokunaga K, Iida S. Peristomal Moisture-Associated Skin Damage and Independence in Pouching System Changes in Persons With New Fecal Ostomies. *J Wound Ostomy Continence Nurs.* 2019 Mar/Apr;46(2):137-142. DOI: 10.1097/WON.0000000000000491
39. Hall A, Sexton J, Lynch B, Boecker F, Davis EP, Sturgill E, et al. Frostbite and immersion foot care. *Mil Med.* 2018 Sep 1;183(suppl\_2):168-171. DOI: 10.1093/milmed/usy085
40. Bush JS, Watson S, Lofgran T. Trench foot. *StatPearls.* 2023 Aug 8. Available from: [www.ncbi.nlm.nih.gov/books/NBK482364](http://www.ncbi.nlm.nih.gov/books/NBK482364)
41. Kuhnke JL, Wright G, Kapteyn R. Wound care in a drop-in and rehabilitation center: a Calgary perspective. *Wound Care Canada.* 2015;13(2):6. Available from: <https://www.woundscanada.ca/docman/public/wound-care-canada-magazine/2015-vol-13-no-2/547-wcc-fall-2015-v13n2-calgary-drop-in/file>
42. Olson Z, Kman N. Immersion foot: a case report. *J Emerg Med.* 2015 Aug;49(2):e45-8. DOI: 10.1016/j.jemermed.2015.02.040
43. Mistry K, Ondhia C, Levell NJ. A review of trench foot: a disease of the past in the present. *Clin Exp Dermatol.* 2020 Jan;45(1):10-14. DOI: 10.1111/ced.14031
44. Kravets OV, Yekhalov VV, Trofimov NV, Sedinkin VA, Martynenko DA. Trench foot and other non-freezing cold injuries (literature review). *Emergency Medicine (Ukraine).* 2022 Dec 27;18(8):7-13. DOI: 10.22141/2224-0586.18.8.2022.1538
45. Sachs C, Lehnhardt M, Daigeler A, Goertz O. The triaging and treatment of cold-induced injuries. *Dtsch Arztebl Int.* 2015 Oct 30;112(44):741-7. DOI: 0.3238/arztebl.2015.0741
46. Zafren K. Nonfreezing cold water (trench foot) and warm water immersion injuries. *UpToDate.* 2024 Jan. Available from: <https://www.uptodate.com/contents/nonfreezing-cold-water-trench-foot-and-warm-water-immersion-injuries>
47. Nundy S, Cooper LA, Mate KS. The quintuple aim for health care improvement: a new imperative to advance health equity. *JAMA.* 2022 Feb 8;327(6):521-522. DOI: 10.1001/jama.2021.25181
48. Orsted HL, Keast DH, Forest-Lalande L, Kuhnke JL, O'Sullivan-Drombolis D, Jin S, et al. Skin: anatomy, physiology and wound healing. In: Kuhnke JL, Burrows CA, Evans RM, Orsted HL, Rosenthal S, editors. *Best practice recommendations for skin health and wound management 2025.* Toronto (ON): Wounds Canada; 2025. DOI: 10.56885/PEWY3827
49. Orsted HL, Keast DH, Forest-Lalande L, Kuhnke JL, O'Sullivan-Drombolis D, Jin S, et al. Best practice recommendations for the prevention and management of wounds: an overview. In: Kuhnke JL, Burrows CA, Evans RM, Orsted HL, Rosenthal S, editors. *Best practice recommendations for skin health and wound management 2025.* Toronto (ON): Wounds Canada; 2025. DOI: 10.56885/CVEU6924
50. Registered Nurses' Association of Ontario (RNAO). A proactive approach to bladder and bowel management in adults. Toronto (ON); 2020 Dec. Available from: <https://rnao.ca/bpg/guidelines/proactive-approach-bladder-and-bowel-management-adults>
51. McNichol L, Bliss DZ, Gray M. Moisture-associated skin damage: expanding practice based on the newest icd-10-cm codes for irritant contact dermatitis associated with digestive secretions and fecal or urinary effluent from an abdominal stoma or enterocutaneous fistula. *J Wound Ostomy Continence Nurs.* 2022 May-Jun 01;49(3):235-239. DOI: 10.1097/WON.0000000000000873
52. Power L, Mullally D, Gibney ER, Clarke M, Visser M, Volkert D, et al.; MaNuEL Consortium. A review of the validity of malnutrition screening tools used in older adults in community and health-care settings - a MaNuEL study. *Clin Nutr ESPEN.* 2018 Apr;24:1-13. DOI: 10.1016/j.clnesp.2018.02.005
53. Ichikawa-Shigeta Y, Sugama J, Sanada H, Nakatani T, Konya C, Nakagami G, et al. Physiological and appearance characteristics of skin maceration in elderly women with incontinence. *J Wound Care.* 2014 Jan;23(1):18-9, 22-23, 26 passim. DOI: 10.12968/jowc.2014.23.1.18
54. LeBlanc K, Christensen D, Robbs L, Johnston V, Cleland B, Flett N. Best practice recommendations for the prevention and management of incontinence-associated dermatitis. *Wound Care Canada.* 2010;8(3):6-23. Available from: <https://www.woundscanada.ca/docman/public/wound-care-canada-magazine/2010-vol-8-no-3/597-vol8no3full/file>
55. Gray M, Giuliano KK. Incontinence-associated dermatitis, characteristics and relationship to pressure injury: a multisite epidemiologic analysis. *J Wound Ostomy Continence Nurs.* 2018 Jan/Feb;45(1):63-67. DOI: 10.1097/WON.0000000000000390
56. Nix DH. Validity and reliability of the Perineal Assessment Tool. *Ostomy Wound Manage.* 2002 Feb;48(2):43-6, 48-9.
57. Li YM, Lee HH, Lo YL, Chao HL. Perineal Assessment Tool (PAT-C): validation of a Chinese language version and identification of a clinically validated cut point using roc curve analysis. *J Wound Ostomy Continence Nurs.* 2019 Mar/Apr;46(2):150-153. DOI: 10.1097/won.0000000000000510

58. Beeckman D, Van den Bussche K, Alves P, Arnold Long MC, Beele H, Ciprandi G, et al. Towards an international language for incontinence-associated dermatitis (IAD): design and evaluation of psychometric properties of the Ghent Global IAD Categorization Tool (GLOBIAD) in 30 countries. *Br J Dermatol*. 2018 Jun;178(6):1331-1340. DOI: 10.1111/bjd.16327
59. Van den Bussche K, Verhaeghe S, Van Hecke A, Beeckman D. The Ghent Global IAD Monitoring Tool (GLOBIAD-M) to monitor the healing of incontinence-associated dermatitis (IAD): Design and reliability study. *Int Wound J*. 2018 Aug;15(4):555-564. DOI: 10.1111/iwj.12898
60. Borchert K, Bliss DZ, Savik K, Radosevich DM. The incontinence-associated dermatitis and its severity instrument: development and validation. *J Wound Ostomy Continence Nurs*. 2010 Sep-Oct;37(5):527-35. DOI: 10.1097/WON.0b013e3181edac3e
61. Sibbald RG, Kelly J, Lou Kennedy-Evans K, Labrecque C, Waters N. A practical approach to the prevention and management of intertrigo, or moisture-associated skin damage, due to perspiration: expert consensus on best practice. *Wound Care Canada*. 2013;11(2):22. Available from: <https://www.woundscanada.ca/docman/public/71-bpr-prevention-management-fall-2013/fil>
62. Thompson N, Gordey L, Bowles H, Parslow N, Houghton P. Reliability and validity of the revised photographic wound assessment tool on digital images taken of various types of chronic wounds. *Adv Skin Wound Care*. 2013 Aug;26(8):360-373. DOI: 10.1097/01.ASW.0000431329.50869.6f
63. Bates-Jensen BM, McCreath HE, Harputlu D, Patlan A. Reliability of the Bates-Jensen wound assessment tool for pressure injury assessment: the pressure ulcer detection study. *Wound Repair Regen*. 2019 Jul;27(4):386-395. DOI: 10.1111/wrr.12714
64. Pillen H, Miller M, Thomas J, Puckridge P, Sandison S, Spark JI. Assessment of wound healing: validity, reliability and sensitivity of available instruments. *Wound Practice & Research: Journal of the Australian Wound Management Association*. 2009 Nov;17(4):208-17. Available from: <https://search.informit.org/doi/abs/10.3316/informit.328226456517348>
65. Martins L, Ayello EA, Claessens I, Steen Hansen A, Hentze Poulsen L, Sibbald RG, et al. The ostomy skin tool: tracking peristomal skin changes. *Br J Nurs*. 2010 Aug;19(15):960, 932-4. DOI: 10.12968/bjon.2010.19.15.77691
66. Jemec GB, Martins L, Claessens I, Ayello EA, Hansen AS, Poulsen LH, et al. Assessing peristomal skin changes in ostomy patients: validation of the Ostomy Skin Tool. *Br J Dermatol*. 2011 Feb;164(2):330-5. DOI: 10.1111/j.1365-2133.2010.10093.x
67. Martins L, Down G, Andersen BD, Nielsen LF, Hansen AS, Herschend NO, et al. The Ostomy Skin Tool 2.0: a new instrument for assessing peristomal skin changes. *Br J Nurs*. 2022 Apr 21;31(8):442-450. DOI: 10.12968/bjon.2022.31.8.442
68. Antonini M, Militello G, Manfreda S, Arena R, Veraldi S, Gasperini S. A revised version of the original SACS Scale for Peristomal Skin Disorders Classification. *World Council of Enterostomal Therapists Journal*. 2016 Jul;36(3):22-9. Available from: <https://search.informit.org/doi/abs/10.3316/informit.361794847146066>
69. Bosio G, Pisani F, Lucibello L, Fonti A, Scrocca A, Morandell C, et al. A proposal for classifying peristomal skin disorders: results of a multicenter observational study. *Ostomy Wound Manage*. 2007 Sep;53(9):38-43.
70. Beeckman D. A decade of research on Incontinence-Associated Dermatitis (IAD): evidence, knowledge gaps and next steps. *J Tissue Viability*. 2017 Feb;26(1):47-56. DOI: 10.1016/j.jtv.2016.02.004
71. Arnold-Long M, Emmons K, Chovan JD. Incontinence-associated dermatitis and intertriginous dermatitis as nurse-sensitive quality indicators: a Delphi study. *J Wound Ostomy Continence Nurs*. 2018 May/Jun;45(3):221-226 DOI: 10.1097/WON.0000000000000427
72. Faust E, McCoulough S, Idensohn P. Understanding moisture-associated skin damage and best practice recommendations. *Wound Care Today*. 2022;68(suppl 5):S1-4. Available from: [https://www.woundcare-today.com/uploads/files/documents/MASD-Special-Report\\_0525.pdf](https://www.woundcare-today.com/uploads/files/documents/MASD-Special-Report_0525.pdf)
73. Bryant R, Nix DP. *Acute and chronic wounds: current management concepts*. 5th ed. Amsterdam: Elsevier Academic Press Inc; 2016.
74. Rolstad BS, Ermer-Seltun J, Bryant RA. Relating knowledge of anatomy and physiology to peristomal skin care. *Gastrointestinal Nursing*. 2011 Nov;9(Sup3):3-9. DOI: 10.12968/gasn.2011.9.Sup3.3
75. Burch J. Stoma product selection: an update. *Br J Community Nurs*. 2023 Apr 2;28(4):188-192. DOI: 10.12968/bjcn.2023.28.4.188
76. Whitaker J. Non-freezing cold injury, lessons from history for future prevention. *Trauma*. 2016 Jul;18(3):178-85. DOI: 10.1177/1460408615617
77. Nygaard RM, Lacey AM, Lemere A, Dole M, Gayken JR, Lambert Wagner AL, et al. Time matters in severe frostbite: assessment of limb/digit salvage on the individual patient level. *J Burn Care Res*. 2017 Jan/Feb;38(1):53-59. DOI: 10.1097/BCR.0000000000000426
78. Wang X, Zhang Y, Zhang X, Zhao X, Xian H. Incidence and risk factors of incontinence-associated dermatitis among patients in the intensive care unit. *J Clin Nurs*. 2018 Nov;27(21-22):4150-4157. DOI: 10.1111/jocn.14594
79. Vale TA, Symmonds M, Polydefkis M, Byrnes K, Rice ASC, The-mistocopathic pain due to a sensory neuropathy. *Brain*. 2017 Oct 1;140(10):2557-2569. DOI: 10.1093/brain/awx215
80. Meyer I, Richter HE. Impact of fecal incontinence and its treatment on quality of life in women. *Womens Health (Lond)*. 2015 Mar;11(2):225-38. DOI: 10.2217/whe.14.66
81. Zarowitz BJ, Allen C, O'Shea T, Tangalos E, Berner T, Ouslander JG. Clinical burden and nonpharmacologic management of nursing facility residents with overactive bladder and/or urinary incontinence. *Consult Pharm*. 2015 Sep;30(9):533-42. DOI: 10.4140/TCP.n.2015.533
82. Barrow JM. Promoting health-behavior changes in patients. *American Nurse Today*. 2013 Nov 1;8(11):43-6. Available from: <https://www.myamericannurse.com/promoting-health-behavior-changes-in-patients/>
83. Agency for Healthcare Research and Quality. 2014 national healthcare quality & disparities report. Rockwell (MD): Agency for Healthcare Research and Quality; 2015 May. Available from: <https://archive.ahrq.gov/research/findings/nhqdr/nhqdr14/2014nhqdr.pdf>
84. Goto T, Wang C, Kwiat C, Nguyen C, Saligan LN. Community-based wound care programs for unhoused individuals. *J Epidemiol Glob Health*. 2023 Dec;13(4):604-614. DOI: 10.1007/s44197-023-00157-6
85. Wolf R, Oumeish OY, Parish LC. Intertriginous eruption. *Clin Dermatol*. 2011 Mar-Apr;29(2):173-9. DOI: 10.1016/j.clindermatol.2010.09.009
86. Queens' Nursing Institute. The foot health of people experiencing homelessness. 2020. Available from: <https://qni.org.uk/wp-content/uploads/2016/09/The-Foot-Health-of-People-Experiencing-Homelessness-2020-1.pdf>

87. Registered Nurses' Association of Ontario (RNAO). Strategies to support self-management in chronic conditions: collaboration with clients. Toronto (ON): RNAO; 2010 Sep. Available from: <https://rnao.ca/bpg/guidelines/strategies-support-selfmanagement-chronic-conditions-collaboration-clients>
88. Budri AMV, McEvoy NL. Moisture-associated skin damage: a framework to guide decision making. *Br J Nurs*. 2022 Aug 11;31(15):S4-S6. DOI: 10.12968/bjon.2022.31.15.S4
89. Rutherford M. Standardized nursing language: what does it mean for nursing practice. *OJIN: The Online Journal of Issues in Nursing*. 2008 Jan 1;13(1):1-9. DOI: 10.3912/OJIN.Vol13No01PPT05
90. Tay C, Yuh AS, Sheau Lan EL, Ong CE, Aloweni F, Lopez V. Development and validation of the incontinence associated dermatitis knowledge, attitude and practice questionnaire. *J Tissue Viability*. 2020 Nov;29(4):244-251. DOI: 10.1016/j.jtv.2020.06.004
91. Boyles A, Voegeli D, Beeckman D, Fletcher J, Kottner J, McNichol L, et al. Best practice recommendations: prevention and management of moisture-associated skin damage (MASD). *Wounds International*. 2020 Oct 5:1-20. Available from: <https://woundsinternational.com/best-practice-statements/best-practice-recommendations-prevention-and-management-moisture-associated-skin-damage-masd/>
92. Frings VG, Böer-Auer A, Breuer K. Histomorphology and immunophenotype of eczematous skin lesions revisited-skin biopsies are not reliable in differentiating allergic contact dermatitis, irritant contact dermatitis, and atopic dermatitis. *Am J Dermatopathol*. 2018 Jan;40(1):7-16. DOI: 10.1097/DAD.0000000000000842
93. Nobles T, Miller RA. Intertrigo. Treasure Island (FL): StatPearls Publishing; 2018. Retrieved from: [www.ncbi.nlm.nih.gov/books/NBK531489](http://www.ncbi.nlm.nih.gov/books/NBK531489)
94. Dowsett C, Protz K, Drouard M, Harding KG. Triangle of wound assessment made easy. *Wounds International*. 2015. Retrieved from: [www.woundsinternational.com/uploads/resources/1f92ba4128e-b6a7d452f7c307ab23090.pdf](http://www.woundsinternational.com/uploads/resources/1f92ba4128e-b6a7d452f7c307ab23090.pdf)
95. Gray M, Black JM, Baharestani MM, Bliss DZ, Colwell JC, et al. Moisture-associated skin damage: overview and pathophysiology. *J Wound Ostomy Continence Nurs*. 2011 May-Jun;38(3):233-41. DOI: 10.1097/won.0b013e318215f798
96. Imray CH, Richards P, Greeves J, Castellani JW. Nonfreezing cold-induced injuries. *J R Army Med Corps*. 2011 Mar;157(1):79-84. DOI: 10.1136/jramc-157-01-14
97. Banharak S, Panpanit L, Subindee S, Narongsanoi P, Sanun-Aur P, Kulwong W, et al. Prevention and care for incontinence-associated dermatitis among older adults: a systematic review. *J Multidiscip Healthc*. 2021 Oct 26;14:2983-3004. DOI: 10.2147/JMDH.S329672
98. Sibbald RG, Elliott JA, Persaud-Jaimangal R, Goodman L, Armstrong DG, Harley C, et al. Wound bed preparation 2021. *Adv Skin Wound Care*. 2021 Apr 1;34(4):183-195. DOI: 10.1097/01.ASW.0000733724.87630.d6
99. Chatham N, Carls C. How to manage incontinence-associated dermatitis. *Wound care advisor*. 2012 May;1(1):7-10. Available from: <https://woundcareadvisor.com/how-to-manage-incontinence-associated-dermatitis/>
100. Voegeli D. Moisture-associated skin damage: an overview for community nurses. *Br J Community Nurs*. 2013 Jan;18(1):6, 8, 10-2. DOI: 10.12968/bjcn.2013.18.1.6
101. Moore Z, Butcher G, Corbett LQ, McGuinness W, Snyder RJ, van Acker K. Exploring the concept of a team approach to wound care: managing wounds as a team. *J Wound Care*. 2014 May;23 Suppl 5b:S1-S38. DOI: 10.12968/jowc.2014.23.Sup5b.S1
102. Budri AMV, McEvoy NL. Moisture-associated skin damage: a framework to guide decision making. *Br J Nurs*. 2022 Aug 11;31(15):S4-S6. DOI: 10.12968/bjon.2022.31.15.S4
103. Tol A, Alhani F, Shojaezadeh D, Sharifirad G, Moazam N. An empowering approach to promote the quality of life and self-management among type 2 diabetic patients. *J Educ Health Promot*. 2015 Mar 26;4:13. DOI: 10.4103/2277-9531.154022
104. Vahdat S, Hamzehgardeshi L, Hessam S, Hamzehgardeshi Z. Patient involvement in health care decision making: a review. *Iran Red Crescent Med J*. 2014 Jan;16(1):e12454.
105. Bombard Y, Baker GR, Orlando E, Fancott C, Bhatia P, Casalino S, et al. Engaging patients to improve quality of care: a systematic review. *Implement Sci*. 2018 Jul 26;13(1):98. DOI: 10.1186/s13012-018-0784-z
106. Ott CLB, Jones-Lim L, Bandali A, Calabrese S. How we decreased the cost of wound care supplies at a hospital and long-term-care home. *Wound Care Canada*. 2018;16(2), 58-61. Available from: <https://www.woundscanada.ca/docman/public/wound-care-canada-magazine/2018-vol-16-no-2/1344-how-we-decreased-the-cost-of-wound-care-supplies/file>
107. Norman RE, Gibb M, Dyer A, Prentice J, Yelland S, Cheng Q, et al. Improved wound management at lower cost: a sensible goal for Australia. *Int Wound J*. 2016 Jun;13(3):303-16. DOI: 10.1111/iwj.12538
108. Norton L, Parslow N, Ho C, O'Sullivan-Drombolis D, Rogers A, Parsons A et al. Best practice recommendations for the prevention and management of pressure injuries. In: Kuhnke JL, Burrows CA, Evans RM, Orsted HL, Rosenthal S, editors. *Best practice recommendations for skin health and wound management 2025*. Toronto (ON): Wounds Canada; 2025. DOI: 10.56885/GRYI5585
109. Jin S. A pharmacist's role in wound care. *Wound Care Canada*. 2015 Fall;13(2):4. Available from: <https://www.woundscanada.ca/docman/public/wound-care-canada-magazine/2015-vol-13-no-2/540-wcc-fall-2015-v13n2-day-in-the-life/file>
110. Gray M, Bliss DZ, McNichol L, Cartwright D. Moisture-associated skin damage: a historic step forward. *J Wound Ostomy Continence Nurs*. 2021 Nov-Dec 01;48(6):581-583. DOI: 10.1097/WON.0000000000000827
111. McNichol L, Bliss DZ, Gray M. Moisture-associated skin damage: expanding practice based on the newest icd-10-cm codes for irritant contact dermatitis associated with digestive secretions and fecal or urinary effluent from an abdominal stoma or enterocutaneous fistula. *J Wound Ostomy Continence Nurs*. 2022 May-Jun 01;49(3):235-239. DOI: 10.1097/won.0000000000000873
112. Van Damme N, Van Hecke A, Himpens A, Verhaeghe S, Beeckman D. Design and psychometric testing of the attitude towards the prevention of incontinence-associated dermatitis instrument (APrIAD). *Int Wound J*. 2019 Apr;16(2):492-502. DOI: 10.1111/iwj.13062
113. Woo KY, Beeckman D, Chakravarthy D. Management of moisture-associated skin damage: a scoping review. *Adv Skin Wound Care*. 2017 Nov;30(11):494-501. DOI: 10.1097/01.ASW.0000525627.54569.da
114. Alavi A, Sibbald RG, Ladizinski B, Saraiya A, Lee KC, Skotnicki-Grant S, et al. Wound-related allergic/irritant contact dermatitis. *Adv Skin Wound Care*. 2016 Jun;29(6):278-86. DOI: 10.1097/01.ASW.0000482834.94375.1e
115. Erfurt-Berge C, Geier J, Mahler V. The current spectrum of contact sensitization in patients with chronic leg ulcers or stasis dermatitis - new data from the Information Network of Departments of Dermatology (IVDK). *Contact Dermatitis*. 2017 Sep;77(3):151-158. DOI: 10.1111/cod.12763
116. Artüz F, Yılmaz E, Külcü Çakmak S, Polat Düzgün A. Contact sensitisation in patients with chronic leg ulcers. *Int Wound J*. 2016 Dec;13(6):1190-1192. DOI: 10.1111/iwj.12442

117. Lewis RJ, Touma S. Contact dermatitis presenting as cellulitis after wound care treatment. *West Virginia Medical Journal*. 2017 Jul 1;113(4):32-4. Available from: <https://go.gale.com/ps/i.do?p=HR-CA&u=googlescholar&id=GALE|A504543903&v=2.1&it=r&sid=googleScholar&asid=b5e44ff8>
118. Mugita Y, Koudounas S, Nakagami G, Weller C, Sanada H. Assessing absorbent products' effectiveness for the prevention and management of incontinence-associated dermatitis caused by urinary, faecal or double adult incontinence: A systematic review. *J Tissue Viability*. 2021 Nov;30(4):599-607. DOI: 10.1016/j.jtv.2021.07.002
119. Gray M, Weir D. Prevention and treatment of moisture-associated skin damage (maceration) in the periwound skin. *J Wound Ostomy Continence Nurs*. 2007 Mar-Apr;34(2):153-7. DOI: 10.1097/01.WON.0000264827.80613.05
120. Forest-Lalande L. Feeding gastrostomies: prevention and management of tube-related complications. *WCET Journal (Needs for Peds)*. 2010;32(3):22-27.
121. LeBlanc K, Whiteley I, McNichol L, Salvadalena G, Gray M. Peristomal medical adhesive-related skin injury: results of an international consensus meeting. *J Wound Ostomy Continence Nurs*. 2019 Mar/Apr;46(2):125-136. DOI: 10.1097/WON.0000000000000513
122. Murphy C, Atkin L, Swanson T, Tachi M, Tan YK, de Ceniga MV, et al. Defying hard-to-heal wounds with an early antibiofilm intervention strategy: wound hygiene. *J Wound Care*. 2020 Mar 1;29(Sup3b):S1-S26. DOI: 10.12968/jowc.2020.29.Sup3b.S1
123. McNichol LL, Ayello EA, Phearman LA, Pezzella PA, Culver EA. Incontinence-associated dermatitis: state of the science and knowledge translation. *Adv Skin Wound Care*. 2018 Nov;31(11):1. DOI: 10.1097/01.ASW.0000546234.12260.61
124. Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. *Drug Saf*. 2015 May;38(5):493-509. DOI: 10.1007/s40264-015-0287-7
125. Earlam AS, Woods L. Moisture-associated skin damage: the basics. *American Nurse Today*. 2022;17(10):6-11. Available from: <https://www.myamericannurse.com/moisture-associated-skin-damage/>
126. Michaelis TC, Neill BC, Patel V, Aires DJ, Rajpara AN. Significant cost savings from treating peristomal irritant contact dermatitis with an over-the-counter spray. *J Am Acad Dermatol*. 2017 May;76(5):e167. DOI: 10.1016/j.jaad.2016.12.022
127. Chuang WL, Huang WP, Chen MH, Liu IP, Yu WL, Chin CC. Gauze versus solid skin barrier for tracheostomy care: a crossover randomized clinical trial. *J Wound Ostomy Continence Nurs*. 2013 Nov-Dec;40(6):573-9. DOI: 10.1097/01.WON.0000436431.01159.9f
128. Mendes B, Salomé GM, Pinheiro FAM, Júnior MRM, da Cunha DR, Ferreira LM. Preventing and treating trench foot: validation of an educational manual for military personnel. *J Wound Care*. 2018 Oct 1;27(Sup10):S33-S38. DOI: 10.12968/jowc.2018.27.Sup10.S33
129. Anand P, Privitera R, Yiangou Y, Donatien P, Birch R, Misra P. Trench foot or non-freezing cold injury as a painful vaso-neuropathy: clinical and skin biopsy assessments. *Front Neurol*. 2017 Sep 29;8:514. DOI: 10.3389/fneur.2017.00514
130. To MJ, Brothers TD, Van Zoost C. Foot conditions among homeless persons: a systematic review. *PLoS One*. 2016 Dec 9;11(12):e0167463. DOI: 10.1371/journal.pone.0167463
131. Gray M, Beeckman D, Bliss DZ, Fader M, Logan S, Junkin J, et al. Incontinence-associated dermatitis: a comprehensive review and update. *J Wound Ostomy Continence Nurs*. 2012 Jan-Feb;39(1):61-74. DOI: 10.1097/WON.0b013e31823fe246
132. Beeckman D, Van Lancker A, Van Hecke A, Verhaeghe S. A systematic review and meta-analysis of incontinence-associated dermatitis, incontinence, and moisture as risk factors for pressure ulcer development. *Res Nurs Health*. 2014 Jun;37(3):204-18. DOI: 10.1002/nur.21593
133. Copson D, Cotterell RL, Bouthflower R. Managing intertriginous dermatitis (intertrigo) with a total barrier protection TM strategy. *Wounds UK*. 2020 Nov 6;16(4):66-71. Available from: <https://wounds-uk.com/journal-articles/managing-intertriginous-dermatitis-intertrigo-total-barrier-protectiontm-strategy/>